Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
BMC Cancer
    November 2026
  1. KIPKOECH M, Beck CM, Jaeger A, Blume K, et al
    Linking dietary-derived arsenic exposure to blood serum arsenic burden, potential food sources, and breast cancer risk in the EPIC-Heidelberg cohort.
    BMC Cancer. 2026;26:1406.
    >> Share

    October 2026
  2. SALZER AT, Williams C, Skoluda S, Stylianou M, et al
    Neutrophils alter the metabolic profile of a coculture model of triple-negative breast cancer and stromal cells.
    BMC Cancer. 2026;26:1272.
    >> Share

  3. REISIG E, Cai L, Muller M, Schafgen B, et al
    Machine learning model for the prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer.
    BMC Cancer. 2026;26:1229.
    >> Share

  4. PETLELE R, Chikwati RP, Ojoniyi OO, Akokuwebe ME, et al
    Impact of and recovery after Covid-19 on breast cancer diagnosis and care in Johannesburg, South Africa.
    BMC Cancer. 2026;26:1182.
    >> Share

  5. WASTI SA, Gill S, Jamshed A, Noor M, et al
    Real-world effectiveness and safety of neoadjuvant pembrolizumab in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2026;26:1392.
    >> Share

    September 2026
  6. AYDIN O, Dogan HGY, Sonusen SD, Erciyestepe M, et al
    The effect of adding ovarian function suppression to adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive, HER2-positive breast cancer who have undergone neoadjuvant therapy: a single-center experience.
    BMC Cancer. 2026;26:1140.
    >> Share

    August 2026
  7. SARATHCHANDRA S, Fittipaldi C, Alamukii NA, Kovacs A, et al
    Spheroid cultures reveal cancer stem cell enrichment and distinct chemotherapeutic response in triple-negative breast cancer.
    BMC Cancer. 2026;26:994.
    >> Share

  8. KAVGACI G, Sahin TK, Guduk N, Sirvan F, et al
    Potential prognostic value of the free T3/T4 ratio in HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
    BMC Cancer. 2026;26:1394.
    >> Share

  9. ZHANG S, Dong S, Chen Y, Yu Y, et al
    Combined morphology and distribution features for risk stratification in pathology-enriched BI-RADS 4A/4B microcalcifications.
    BMC Cancer. 2026;26:1385.
    >> Share

  10. SUN W, Wang W, Zhang Q, Zhao J, et al
    Integrating a Ripple Filter into Pencil Beam Scanning Proton Therapy for Breast Cancer: from Dosimetric Feasibility to Acute Toxicity Assessment.
    BMC Cancer. 2026;26:1386.
    >> Share

  11. POLANCO ER, Moustafa TE, Balcioglu O, Scherer SD, et al
    Determination of drug sensitivity in patient derived models of breast cancer by multiparametric quantitative phase imaging.
    BMC Cancer. 2026;26:1384.
    >> Share

  12. ANANGA NOA SA, Dina Bell E, Anaba D, Ndengue CP, et al
    FOSL2 expression in histologically diagnosed breast cancer: first immunohistochemical evidence from Cameroon.
    BMC Cancer. 2026;26:1381.
    >> Share

  13. WANG X, Liu S, Tang L
    Dynamic changes in ER, PR, HER2, Ki-67, and AR before and after neoadjuvant therapy in breast cancer and their clinicopathological significance: a single-center real-world study.
    BMC Cancer. 2026;26:1375.
    >> Share

  14. OMRANIPOUR R, Bayat M, Alipour S, Banigol F, et al
    Association between neoadjuvant and adjuvant chemotherapy and severity of breast cancer-related lymphedema following axillary lymph node dissection.
    BMC Cancer. 2026;26:1369.
    >> Share

  15. YU L, Shi Q, Jin Y, Liu Z, et al
    Retraction Note: Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study.
    BMC Cancer. 2026;26:944.
    >> Share

  16. AZIZI S, Hosseinpour Z, Akbari A, Akbari ME, et al
    Family history and stage at diagnosis but not prognosis in female breast cancer: a large registry-based cohort study from Iran.
    BMC Cancer. 2026;26:1339.
    >> Share

  17. SEYYAR M, Sanci PC, Dogan A, Biter S, et al
    Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group.
    BMC Cancer. 2026;26:1047.
    >> Share

  18. ZHANG YJ, Liang ZM, Huang XY, Yu YJ, et al
    Pre-treatment prediction of response to neoadjuvant chemotherapy in breast cancer patients using a nomogram based on findings from cone-beam breast computed tomography.
    BMC Cancer. 2026;26:1318.
    >> Share

    July 2026
  19. PRADO V, Esperanca G, Nahas GP, Maya BG, et al
    Metabolic health at breast cancer diagnosis and two-year survival: a prospective cohort study in a public healthcare setting.
    BMC Cancer. 2026;26:1309.
    >> Share

  20. CONCATO-LOPES VM, Cruz EMS, de Lima LVA, Goncalves-Lens MD, et al
    The biphenyl dimeric compound 3,3',5,5'-tetramethoxybiphenyl-4,4'-diol disrupts redox homeostasis and mitochondrial function to inhibit growth and induce apoptosis in breast cancer monolayers and 3D tumor spheroids.
    BMC Cancer. 2026;26:1306.
    >> Share

  21. ZHANG S, Xu L, Peng W
    A novel Hemoglobin-Albumin-Lymphocyte-Platelet (HALP)-based prognostic model to predict the progression of premenopausal breast cancer: a retrospective cohort study.
    BMC Cancer. 2026;26:1294.
    >> Share

  22. WRIGHT FM, Vasileva-Slaveva M, Yordanov A, Ivanov I, et al
    Characterisation of a novel p53 mutation (p53(N263Tfs*7)) associated with li-fraumeni syndrome.
    BMC Cancer. 2026;26:1297.
    >> Share

  23. ALMEIDA NR, Brenelli FP, de Paula Leite Kraft MB, de Azevedo NS, et al
    Survival implications of non-organized breast cancer screening in a Brazilian tertiary women's health center: a retrospective cohort study of 1517 patients.
    BMC Cancer. 2026;26:1284.
    >> Share

  24. CHANG X, Zuo S, Wang Z, Wang Z, et al
    Sleep patterns and breast cancer risk: a prospective cohort study integrating multi-omics and machine learning.
    BMC Cancer. 2026;26:1282.
    >> Share

  25. MUZI CD, Veggi AB, Coutinho RPM, Albuquerque DBS, et al
    Regional divergence in female cancer mortality in Brazil signals the unequal pace of the cancer transition.
    BMC Cancer. 2026;26:1279.
    >> Share

  26. TIAN L, Feng X, Liu M, Jiang J, et al
    Construction and validation of a predictive model for fear of progression among postoperative patients with breast cancer: a multi-center cross-sectional study.
    BMC Cancer. 2026;26:1267.
    >> Share

  27. ZHAO S, He S, Zhou Y, Fan Y, et al
    Clinicopathologic features and prognostic factors of breast cancer brain metastases patients based on molecular subtypes: a real-world retrospective analysis.
    BMC Cancer. 2026;26:1275.
    >> Share

  28. PARK SY, Kim YJ, Chae H, Choi YJ, et al
    Information-seeking experiences during genetic testing and counseling: a qualitative study of patients at high risk for hereditary breast cancer.
    BMC Cancer. 2026 Jul 21. doi: 10.1186/s12885-026-16538.
    >> Share

  29. GAO J, Wang S, Zhang Z, Li J, et al
    Retraction Note: Long non-coding RNA BRE-AS1 inhibits the proliferation, migration, and invasion of cancer cells in triple-negative breast cancer and predicts patients' survival by downregulating miR-21.
    BMC Cancer. 2026;26:870.
    >> Share

  30. NGUYEN HT, Vu MD, Nguyen DD, Dinh PN, et al
    Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients.
    BMC Cancer. 2026;26:858.
    >> Share

  31. SHEN K, Cai L, Wu W
    Clinical prognostic value of homologous recombination repair axis markers and PARP1 expression in breast cancer: a systematic review, meta-analysis, and independent cohort validation.
    BMC Cancer. 2026 Jul 15. doi: 10.1186/s12885-026-16530.
    >> Share

  32. SEZAVAR AH, Fakhari F, Jafarzadeh E, Montazeri V, et al
    Capmatinib and paclitaxel combination: a novel strategy for overcoming challenges in triple-negative breast cancer treatment.
    BMC Cancer. 2026 Jul 13. doi: 10.1186/s12885-026-16544.
    >> Share

  33. FERNANDEZ JK, Harris G, Leow BYJ, Beith J, et al
    Curative-intent tri-modality treatment of de novo bone-only oligometastatic breast cancer: single-center patient outcomes.
    BMC Cancer. 2026 Jul 13. doi: 10.1186/s12885-026-16495.
    >> Share

  34. FUJIMOTO A, Ichinose Y, Matsuura K, Mikami E, et al
    Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan.
    BMC Cancer. 2026 Jul 13. doi: 10.1186/s12885-026-16548.
    >> Share

  35. ALABI A, Boateng F, Swanson W, Sowunmi A, et al
    Radiation therapy in breast cancer patients in south west Nigeria: an evaluation of protocols in a specialist cancer centre.
    BMC Cancer. 2026 Jul 10. doi: 10.1186/s12885-026-16483.
    >> Share

  36. ESAN DT, Onabanjo OD, Rasaq NO, Ramos CG, et al
    Illness perception of breast cancer among patients receiving treatment in a university teaching hospital, South-west Nigeria: a qualitative phenomenological study.
    BMC Cancer. 2026 Jul 9. doi: 10.1186/s12885-026-16527.
    >> Share

  37. CHUN K, Tran-Dang MP, Cornett P, Tashombe C, et al
    Outreach to Native Hawaiian and Pacific Islander communities to increase breast cancer screening and clinical trial awareness.
    BMC Cancer. 2026 Jul 8. doi: 10.1186/s12885-026-16493.
    >> Share

  38. DONG F, He S, Wu B, Li J, et al
    The impact of orthogonal image-guided frequency on positioning error correction and dose in postoperative radiotherapy for breast cancer.
    BMC Cancer. 2026 Jul 6. doi: 10.1186/s12885-026-16443.
    >> Share

  39. BHATTACHARYYA S, Thomas JV, Prasad A, Deep A, et al
    Genomic landscape of triple-negative breast cancer in South Asian populations: a systematic review.
    BMC Cancer. 2026 Jul 6. doi: 10.1186/s12885-026-16455.
    >> Share

  40. CHEN Y, Wang D, Li L, Lin T, et al
    Non-linear association between body mass index and port-related thrombosis in breast cancer patients: a retrospective cohort study.
    BMC Cancer. 2026 Jul 4. doi: 10.1186/s12885-026-16488.
    >> Share

  41. XIANG C, Chen X, Mo F, Zhong Z, et al
    Plexin A2 regulated the metastasis in breast cancer through MCM7.
    BMC Cancer. 2026 Jul 3. doi: 10.1186/s12885-026-16355.
    >> Share

  42. HUANG D, Chen Y, Chen W, Wang Y, et al
    A predictive model for pathological complete response in neoadjuvant-treated breast cancer: integrating pretreatment clinicopathologic and contrast-enhanced ultrasound characteristics via interpretable machine learning.
    BMC Cancer. 2026 Jul 3. doi: 10.1186/s12885-026-16452.
    >> Share

  43. YANG Z, Dai Y, Li Y, Xia L, et al
    Routine biomarkers map response probability in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2 blockade.
    BMC Cancer. 2026 Jul 2. doi: 10.1186/s12885-026-16403.
    >> Share

  44. ALKEBBEH L, Berndt A, Oberkanins C, Kenj M, et al
    Comprehensive CYP2D6 genotyping improves phenotype classification and highlights methodological pitfalls in tamoxifen-treated breast cancer.
    BMC Cancer. 2026 Jul 1. doi: 10.1186/s12885-026-16440.
    >> Share

    June 2026
  45. NAKADA K, Takada K, Gose A, Nishimoto M, et al
    Timing and clinical burden of febrile neutropenia and treatment discontinuation during neoadjuvant chemotherapy.
    BMC Cancer. 2026;26:1096.
    >> Share

  46. MEISAMY S, Brattain K, Shao Q, Steinberger D, et al
    Measurement of metabolic activity by telemetric temperature sensing after immunotherapy and chemotherapy on three different mouse tumor models.
    BMC Cancer. 2026;26:1087.
    >> Share

  47. ATCI MM, Erciyestepe M, Erturk K
    Efficacy and tolerability of CDK 4/6 inhibitors in HR-positive HER2-negative de novo metastatic breast cancer patients aged >/= 70 years.
    BMC Cancer. 2026 Jun 25. doi: 10.1186/s12885-026-16430.
    >> Share

  48. SOWERBY C, Lemu K, Landsteiner A, Ullman K, et al
    Comparative efficacy and harms of adjuvant whole breast hypofractionation or external beam accelerated partial breast irradiation for treatment of breast cancer: a systematic review.
    BMC Cancer. 2026 Jun 25. doi: 10.1186/s12885-026-16129.
    >> Share

  49. ANTONIO DNM, Annani-Akollor M, Fondjo LA, Anang-Quartey Y, et al
    Over-presentation of apolipoprotein E gene variants E3/E4 and cardiovascular disease risk factors among Ghanaian breast cancer patients.
    BMC Cancer. 2026 Jun 23. doi: 10.1186/s12885-026-16354.
    >> Share

  50. MO D, Li C, Mao X, Zheng L, et al
    The clinical value of the combined detection of circulating low rectangle density neutrophils and inflammatory markers in breast cancer with lymph node metastasis.
    BMC Cancer. 2026 Jun 23. doi: 10.1186/s12885-026-16384.
    >> Share

  51. GETNET E, Adane G, Awoke Shiferaw E, Ayelegn Nibret T, et al
    Evaluation of tumor-infiltrating lymphocytes across breast cancer stages at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.
    BMC Cancer. 2026 Jun 22. doi: 10.1186/s12885-026-16359.
    >> Share

  52. KARSONO R, Al Azhar M, Utari AD, Perdana AB, et al
    PD-L1 copy number loss is associated with lower survival in women with advanced breast cancer in Indonesian cohort.
    BMC Cancer. 2026 Jun 19. doi: 10.1186/s12885-026-16328.
    >> Share

  53. SALHI I, Maqboul H, Jallad F, Jaradat H, et al
    Immunohistochemical breast cancer subtypes in Palestinian Women: an 18-year multicenter retrospective analysis.
    BMC Cancer. 2026 Jun 18. doi: 10.1186/s12885-026-16319.
    >> Share

  54. LIN LZ, Huang HY, Peng Y, Lin GQ, et al
    Preclinical evaluation of a fluorinated bifendate derivative in triple-negative breast cancer: integrated in vitro and in vivo evidence of antitumor activity.
    BMC Cancer. 2026 Jun 12. doi: 10.1186/s12885-026-16335.
    >> Share

  55. YI C, Xu T, You R, Zhang Q, et al
    Ultrasound-based predictive models for response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2026 Jun 11. doi: 10.1186/s12885-026-16330.
    >> Share

  56. HOUGHTON LC, Ganmaa D, Dos Santos Silva I, Falk R, et al
    Estrogen metabolites in premenopausal women living in China, Mongolia, and the United Kingdom.
    BMC Cancer. 2026;26:1000.
    >> Share

  57. WEI Y, Qi Y, Ge H, Zeng C, et al
    Meta-analysis reveals pathological complete response benefits from neoadjuvant immuno-chemotherapy combination in patients with HER2-negative breast cancer.
    BMC Cancer. 2026 Jun 8. doi: 10.1186/s12885-026-16230.
    >> Share

  58. SHI Y, Fu P, Wang Y, Li Y, et al
    Real-world effectiveness of mecapegfilgrastim for prophylaxis in patients with breast cancer receiving 2-weekly and 3-weekly chemotherapy in China.
    BMC Cancer. 2026 Jun 8. doi: 10.1186/s12885-026-16280.
    >> Share

  59. MA X, Liu X, Ren J, Wang M, et al
    Factors influencing the impact of financial toxicity on the quality of life of breast cancer patients after mastectomies.
    BMC Cancer. 2026 Jun 4. doi: 10.1186/s12885-026-16259.
    >> Share

  60. RADY RAZ N, Nafissi N, Babaee E, Fadavi P, et al
    Breast cancer survival prediction using machine learning and multimodal data for personalized care plan.
    BMC Cancer. 2026 Jun 1. doi: 10.1186/s12885-026-16283.
    >> Share

    May 2026
  61. LIU S, Liu J, Li D, Mo Q, et al
    Development and external validation of multiple machine learning-based models for breast cancer-specific survival prediction in postoperative patients with invasive breast cancer: a study based on the SEER database and an external cohort.
    BMC Cancer. 2026 May 30. doi: 10.1186/s12885-026-16166.
    >> Share

  62. SHEERVALILOU M, Sargazi S, Shahraki S, Sheervalilou R, et al
    Integrated in vitro and bioinformatic analysis of autophagy?related gene expression modulated by Fe(2)O(3)/Au core-shell nanoparticles in breast cancer cells.
    BMC Cancer. 2026 May 29. doi: 10.1186/s12885-026-16068.
    >> Share

  63. WIGUNA IGWW, Sadeva IGKA, Mamangdean CT, Mahayana NPK, et al
    Atezolizumab versus pembrolizumab in the treatment of advanced triple-negative breast cancer: a Bayesian network meta-analysis of ITT and PD-L1 positive populations.
    BMC Cancer. 2026 May 29. doi: 10.1186/s12885-026-16207.
    >> Share

  64. RABANI F, Samadi MH, Sadeghpour S, Barashki S, et al
    [(1)(7)(7)Lu]Lu-FAPI-2286 radioligand therapy in heavily pre-treated patients with advanced breast and gastrointestinal cancers: a single-center retrospective experience.
    BMC Cancer. 2026;26:905.
    >> Share

  65. ALLFELT A, Bendahl PO, Dihge L, Ohlsson M, et al
    Human factors validation study of an artificial neural network?based preoperative decision?support tool for noninvasive lymph node staging (NILS) in women with primary breast cancer (ISRCTN99301435).
    BMC Cancer. 2026 May 28. doi: 10.1186/s12885-026-16161.
    >> Share

  66. AL-QERSHI O, Nguyen TL, Elliott MS, Schmidt DF, et al
    AutoCumulus: an automated mammographic density measure created using artificial intelligence.
    BMC Cancer. 2026;26:900.
    >> Share

  67. OZTURK C, Cubukcu SS, Sen B, Ozturk AE, et al
    High TROP-2 expression as a predictor of poor neoadjuvant chemotherapy response in luminal B breast cancer: a retrospective clinicopathological study.
    BMC Cancer. 2026 May 23. doi: 10.1186/s12885-026-16227.
    >> Share

  68. CELIK O, Ozgul H, Kulaksizoglu S, Oner OZ, et al
    New biomarker in the early diagnosis of breast cancer: adiponectin, asprosin, adropin, and resistin.
    BMC Cancer. 2026 May 22. doi: 10.1186/s12885-026-16183.
    >> Share

  69. GOKCAY G, Efeturk N, Kucuk HI, Ugurlu ES, et al
    Comparison of breast cancer awareness and attitudes toward screenings in women with and without a family history.
    BMC Cancer. 2026 May 20. doi: 10.1186/s12885-026-16155.
    >> Share

  70. GUO X, Li P, Hu S, Ding Y, et al
    Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer: multicenter evidence from China.
    BMC Cancer. 2026 May 20. doi: 10.1186/s12885-026-16176.
    >> Share

  71. KANO M, Furusawa A, Fukushima H, Takao S, et al
    Human epidermal growth factor receptor 3-targeted near-infrared photoimmunotherapy in a xenograft mouse model of breast cancer.
    BMC Cancer. 2026 May 18. doi: 10.1186/s12885-026-16170.
    >> Share

  72. KIRACI M, Soyturk G, Kos FT, Perkin P, et al
    Nailfold capillaroscopy findings after anthracycline-based chemotherapy and their association with subclinical changes in left ventricular ejection fraction.
    BMC Cancer. 2026;26:855.
    >> Share

  73. XIAO WT, He JY, Yang D, Xun Y, et al
    Construction of a novel signature based on CRISPR-Cas9 screening for prognostic prediction in breast cancer.
    BMC Cancer. 2026 May 14. doi: 10.1186/s12885-026-16167.
    >> Share

  74. SETIAWAN G, Azhar Y, Abdurahman M, Soemitro MP, et al
    De-escalation of chemotherapy in HER2-positive breast cancer management: a systematic review and meta-analysis.
    BMC Cancer. 2026 May 14. doi: 10.1186/s12885-026-16149.
    >> Share

  75. SCHIZA A, Digkas E, Papadopoulos F, Skalkidou A, et al
    Endocrine therapy and COVID-19 outcomes in women with breast cancer: a nationwide register- based matched cohort study.
    BMC Cancer. 2026;26:598.
    >> Share

  76. TEPETAM H, Varan MP, Alomari O, Yildirim S, et al
    Cardiotoxicity perspective on the concurrent use of anti-HER2 agents and hypofractionated versus conventional fractionated locoregional radiotherapy in breast cancer.
    BMC Cancer. 2026 May 11. doi: 10.1186/s12885-026-16160.
    >> Share

  77. IHLAMUR M, Demi?rci?oglu A, Zorba AP, Abamor ES, et al
    Evaluating immunoreactivity of hybridoma-derived antibody mixtures generated against AU-565 cell line for diagnosis and immunotherapy of breast cancer.
    BMC Cancer. 2026 May 9. doi: 10.1186/s12885-026-16143.
    >> Share

  78. NAKAUCHI C, Masunaga N, Eguchi Y, Tanei T, et al
    Discordance between IHC/FISH and RNA expression-based assessment of ER/HER2 status, and its prognostic impact assessed by propensity score matching.
    BMC Cancer. 2026;26:808.
    >> Share

  79. AKPALAMUT D, Ellez HI, Atag E, Aktepe OH, et al
    Prognostic factors and survival in elderly breast cancer patients: roles of age, stage and inflammatory markers.
    BMC Cancer. 2026 May 7. doi: 10.1186/s12885-026-16142.
    >> Share

  80. LI H, Chen Y, Guo G, Luo Q, et al
    PPP4C: a potential molecular marker and therapeutic target in thyroid cancer and triple-negative breast cancer.
    BMC Cancer. 2026 May 4. doi: 10.1186/s12885-026-16083.
    >> Share

    April 2026
  81. ANDREOU M, Chojnowska K, Filipowicz N, Horbacz M, et al
    Beyond tumors: uninvolved breast tissue of breast cancer patients with adverse prognoses is enriched for pathogenic PIK3CA and TP53 post-zygotic variants.
    BMC Cancer. 2026 Apr 30. doi: 10.1186/s12885-026-16086.
    >> Share

  82. ERRIHANI H, Berrada N, El Bachiri M, Jouhadi H, et al
    Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco.
    BMC Cancer. 2026 Apr 28. doi: 10.1186/s12885-026-16005.
    >> Share

  83. KESKIN GSY, Turgut GG, Yildirim G, Tuzun EK, et al
    Prognostic value of cachexia index in HR +/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
    BMC Cancer. 2026 Apr 28. doi: 10.1186/s12885-026-16078.
    >> Share

  84. BORG M, Farver-Vestergaard I, Hilberg O, Steed L, et al
    Long-term risk of depression in lung, colon, breast, and prostate cancer: a 25-year nationwide comparative study.
    BMC Cancer. 2026 Apr 28. doi: 10.1186/s12885-026-16095.
    >> Share

  85. QUISENAERTS T, Van Der Auwera I, Poortmans P, Reynders D, et al
    Preoperative Radiation Therapy and Immediate Breast Reconstruction, a phase 3 randomized controlled trial in the Belgian population (PRADAIIBE): a study protocol.
    BMC Cancer. 2026;26:743.
    >> Share

  86. PERERA R, Wijethunga D, Perera M, Abeywickrama C, et al
    Quality of life in breast cancer survivors: insights from a university hospital in Sri Lanka.
    BMC Cancer. 2026 Apr 25. doi: 10.1186/s12885-026-16023.
    >> Share

  87. PARK R, Lee EY, Kang JW, Jun S, et al
    Effect of early exercise on functional recovery and surgical outcomes after post-mastectomy breast reconstruction: study protocol for a randomized clinical trial.
    BMC Cancer. 2026;26:731.
    >> Share

  88. ALBALAWI ES, Qayyum J, Qayyum J
    Population-specific MicroRNA biomarker discovery in breast ductal carcinoma via explainable graph neural multi-omics modeling.
    BMC Cancer. 2026;26:721.
    >> Share

  89. ZHOU Y, Wang X, Li F, Qin H, et al
    MRI quantification of intratumoral heterogeneity for predicting HER2-positive status in breast cancer: a retrospective multicenter study.
    BMC Cancer. 2026 Apr 22. doi: 10.1186/s12885-026-15956.
    >> Share

  90. LIM MSH, Tan SSN, Wan Maharuddin IB, Wan Ali SAB, et al
    Breast cancer survival rates in Sarawak, Malaysia: a central referral centre study.
    BMC Cancer. 2026 Apr 21. doi: 10.1186/s12885-026-16065.
    >> Share

  91. MATKOWSKI R, Abrahamowska M, Michalowska D, Chrusciel A, et al
    Prevalence of recurrent and non-recurrent BRCA1 and BRCA2 pathogenic variants in Polish breast cancer patients: insights from a regional genetic testing cohort from Lower Silesia.
    BMC Cancer. 2026 Apr 21. doi: 10.1186/s12885-026-16017.
    >> Share

  92. YANG X, Hao Z, Yao R, Zhang J, et al
    High TLG measured by PET/CT is associated with worse PFS in patients with advanced HR+ breast cancer treated by abemaciclib combined with endocrine therapy.
    BMC Cancer. 2026 Apr 20. doi: 10.1186/s12885-026-16032.
    >> Share

  93. XIANG Z, Qi X, Liu Y, Zhang F, et al
    Efficacy and safety of ultra-hypofractionated post-operative radiation therapy for breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2026 Apr 18. doi: 10.1186/s12885-026-16020.
    >> Share

  94. NASCIMENTO DW, Filassi JR, Cunha AFT, Goncalves R, et al
    Impact of COVID-19 on breast cancer care - a retrospective cohort study in Brazil.
    BMC Cancer. 2026 Apr 16. doi: 10.1186/s12885-026-15994.
    >> Share

  95. LIU Y, He T, Tang C, Li F, et al
    Single-cell and spatial transcriptome analysis of breast cancer tumor-associated fibroblast heterogeneity and its mediated remodeling of the tumor microenvironment.
    BMC Cancer. 2026 Apr 15. doi: 10.1186/s12885-026-16003.
    >> Share

  96. WIJAYALATHGE H, Peiris K, Jayarajah U, Gunasekara S, et al
    Quality of life following completion of surgery and chemoradiation among Sri Lankan women with breast cancer.
    BMC Cancer. 2026 Apr 13. doi: 10.1186/s12885-026-15991.
    >> Share

  97. CONG B, Hou C, Shan C, Sun S, et al
    Patient-reported outcomes of adjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer: a retrospective cohort study.
    BMC Cancer. 2026 Apr 11. doi: 10.1186/s12885-026-15983.
    >> Share

  98. KOCHI A, Kashiwagi S, Nakada K, Gose A, et al
    Clinical impact of the 21-gene recurrence score on adjuvant treatment selection in elderly patients with hormone receptor-positive, HER2-negative early breast cancer.
    BMC Cancer. 2026 Apr 11. doi: 10.1186/s12885-026-15948.
    >> Share

  99. WALBAUM B, Acevedo F, Segui E, Martinez-Saez O, et al
    Clinical and biomarker predictors of early and late recurrence in hormone receptor-positive breast cancer.
    BMC Cancer. 2026 Apr 10. doi: 10.1186/s12885-026-15998.
    >> Share

  100. QI WX, Ou D, Cao L, Li S, et al
    The PRINCE-BC trial: precision regional irradiation of nodal stations for clinical evaluation of high-risk pN0 breast cancer - a phase III, open-label, randomized controlled trial.
    BMC Cancer. 2026 Apr 7. doi: 10.1186/s12885-026-15971.
    >> Share

  101. ANSARI H, Hajigholami A, Aslani H, Hajigholami A, et al
    Preliminary modeling of brain metastases in breast cancer: a neural network approach to risk factor analysis.
    BMC Cancer. 2026 Apr 7. doi: 10.1186/s12885-026-15954.
    >> Share

  102. NISHIKAWA M, Kashiwagi S, Kochi A, Watanabe C, et al
    Clinical-genomic risk discordance and its impact on treatment selection in premenopausal women with node-positive hormone receptor-positive breast cancer.
    BMC Cancer. 2026 Apr 6. doi: 10.1186/s12885-026-15913.
    >> Share

  103. BARJIJ I, Lamsyah O, Kdadri S, Lkhoyaali S, et al
    Spatial and temporal intratumoral heterogeneity in breast cancer: a systematic and conceptual review of single-cell and spatial omics studies.
    BMC Cancer. 2026 Apr 6. doi: 10.1186/s12885-026-15928.
    >> Share

  104. TADA M, Kikawa Y, Shibata N, Hirai C, et al
    Efficacy of olanzapine for prophylaxis of delayed chemotherapy-induced nausea and vomiting in patients with breast cancer receiving dose-dense AC with a steroid-sparing regimen: a single-center pilot study.
    BMC Cancer. 2026 Apr 6. doi: 10.1186/s12885-026-15962.
    >> Share

  105. XU H, Wang Y, Sa Q, Zhou Y, et al
    Treatment for metastatic triple-negative breast cancer with homologous recombination deficiency: a Bayesian network meta-analysis.
    BMC Cancer. 2026 Apr 2. doi: 10.1186/s12885-026-15947.
    >> Share

  106. WANG Z, Cao Y, Wang Q, Wang L, et al
    Real-world evidence for first-line intrathecal pemetrexed in leptomeningeal metastases from solid tumors: a retrospective cohort study.
    BMC Cancer. 2026;26:651.
    >> Share

  107. HU J, Xiong Z, Wang X
    Prognostic value of pre-treatment serum CA19-9 and lymphocyte-to-monocyte ratio in HR+/HER2- breast cancer: a retrospective cohort study.
    BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15941.
    >> Share

    March 2026
  108. HUANG Z, Muritti C, Sieuwerts A, de Weerd V, et al
    Interrelation between lncRNA HOTAIR and EZH2 expression and progression free survival during endocrine treatment in breast cancer.
    BMC Cancer. 2026 Mar 29. doi: 10.1186/s12885-026-15876.
    >> Share

  109. VERDUIN RJT, van den Hurk CJG, van Maurik IS, Nota NM, et al
    Interactive symptom monitoring and coaching to optimise toxicity management of chemo(immune)therapy in early stage breast cancer: study protocol of the multicentre randomised controlled eChemoCoach trial.
    BMC Cancer. 2026 Mar 26. doi: 10.1186/s12885-026-15905.
    >> Share

  110. FAN M, He S, Wan C, Zhang J, et al
    Joint synthesis of longitudinal MRI and enhanced prediction of neoadjuvant chemotherapy response in breast cancer: a multicohort study.
    BMC Cancer. 2026 Mar 24. doi: 10.1186/s12885-026-15889.
    >> Share

  111. GUPTA R, Gopalsamy IK, Nadukkandy AS, Singh A, et al
    GCNT3 and ST3GAL1 expression correlates with HER2 status and MUC1/beta-catenin/Cyclin D1 axis in breast cancer.
    BMC Cancer. 2026 Mar 19. doi: 10.1186/s12885-026-15821.
    >> Share

  112. FATIREGUN OA, Sutradhar R, Podolsky S, Eisen A, et al
    Mammographic screening and time to breast cancer diagnosis among immigrants and long-term residents in Ontario.
    BMC Cancer. 2026 Mar 19. doi: 10.1186/s12885-026-15693.
    >> Share

  113. LIU S, Li Y, Shen Y, Mao Q, et al
    Redefining M1: a novel three-tiered classification stratifies prognosis in metastatic breast cancer.
    BMC Cancer. 2026 Mar 19. doi: 10.1186/s12885-026-15861.
    >> Share

  114. ATTAH DA, Nsaful J, Sefogah PE
    Coping with breast cancer in Ghana: a qualitative study of women's lived experiences following breast cancer diagnosis.
    BMC Cancer. 2026 Mar 18. doi: 10.1186/s12885-026-15857.
    >> Share

  115. AMUJI DN, Iweala EEJ
    Association of MET gene polymorphisms with breast cancer risk in Nigerian patients: a case-control study.
    BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15844.
    >> Share

  116. ARRARAS JI, Illarramendi JJ, Manterola A, Giesinger JM, et al
    The EORTC updated breast cancer quality of life questionnaire EORTC QLQ-BR42: A psychometric study with Spanish patients.
    BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15831.
    >> Share

  117. GUO HL, Xie HY, Jiang CL, Weng CF, et al
    Surface-guided radiation therapy combined with real-time position management-guided deep inspiratory breath-hold radiotherapy for left breast cancer.
    BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15846.
    >> Share

  118. OZCAN D, Nielsen PS, Alsner J, Nielsen MH, et al
    Associations between tumor immune response and prognosis in node-negative breast cancer patients in the randomized DBCG HYPO trial.
    BMC Cancer. 2026 Mar 13. doi: 10.1186/s12885-026-15859.
    >> Share

  119. MAVILI HS, Atmis O, Pehlivan FS, Ekinci F, et al
    Stromal hypoxia and autophagy signatures as indicators of pathologic response in triple-negative breast cancer.
    BMC Cancer. 2026 Mar 13. doi: 10.1186/s12885-026-15860.
    >> Share

  120. GUCLU T, Tanriverdi O, Bayrakci I, Demir B, et al
    Integration of Ki67 and Pan-Immune-Inflammation Value (PIV) into a predictive nomogram for pathologic complete response in triple-negative breast cancer : (Ki67 and inflammation in triple-negative breast cancer).
    BMC Cancer. 2026 Mar 11. doi: 10.1186/s12885-026-15842.
    >> Share

  121. HAO Y, Jiang X, Xiao J, Fan M, et al
    Genetic evidence for potential molecular mediators underlying the causal relationship between obesity and breast cancer: a two-step, two-sample Mendelian randomization study.
    BMC Cancer. 2026 Mar 10. doi: 10.1186/s12885-026-15744.
    >> Share

  122. GUTIERREZ-GONZALEZ A, Maciel-Cruz EJ, Reynoso-Noveron N, Mohar-Betancourt A, et al
    Impact of germline genetic variation on breast cancer prognosis: a systematic review and meta-analysis.
    BMC Cancer. 2026 Mar 4. doi: 10.1186/s12885-026-15808.
    >> Share

  123. LIU CY, Lin YH, Tsai YF, Lu PY, et al
    Circulating tumor cells (CTCs) enumeration and machine-learning based diagnostic biomarkers for breast cancer detection.
    BMC Cancer. 2026 Mar 3. doi: 10.1186/s12885-026-15741.
    >> Share

    February 2026
  124. XIE Z, Wang K, Liu J, Hong Z, et al
    Stiripentol directly attenuates immunosuppression of tumor-infiltrating myeloid cells to potentiate anti-PD-1 efficacy.
    BMC Cancer. 2026;26:439.
    >> Share

  125. UGUZTEMUR E, Dogan M
    Tumor-Infiltrating lymphocyte dynamics as biomarkers of neoadjuvant treatment response in luminal breast cancer.
    BMC Cancer. 2026 Feb 27. doi: 10.1186/s12885-026-15795.
    >> Share

  126. LEE SF, Cokelek M, Yip PL, Bayley K, et al
    Dosimetric comparison of IMRT and VMAT with deep inspiration breath hold or free breathing for right-sided whole breast irradiation.
    BMC Cancer. 2026;26:429.
    >> Share

  127. FAN Y, Sahoo S, Jolly MK, George JT, et al
    Regulatory network and spatial modeling reveal cooperative mechanisms of resistance and immune escape in ER+ breast cancer.
    BMC Cancer. 2026 Feb 23. doi: 10.1186/s12885-026-15691.
    >> Share

  128. TANG X, Wang T, Shi H, Zhang M, et al
    Breast cancer detection using microscopic images based on composition features.
    BMC Cancer. 2026 Feb 23. doi: 10.1186/s12885-025-15456.
    >> Share

  129. EDET B, Sarimiye FO, Essien E, Lu B, et al
    A cross-sectional study of coping strategies among a sample of women with breast cancer in South-South, Nigeria.
    BMC Cancer. 2026 Feb 19. doi: 10.1186/s12885-026-15770.
    >> Share

  130. BROWNSON-SMITH R, Carr J, Orange ST, Cresti N, et al
    Longitudinal assessment of chemotherapy-induced peripheral neuropathy in women undergoing taxane-based treatment for breast cancer: a prospective observational study.
    BMC Cancer. 2026 Feb 19. doi: 10.1186/s12885-026-15750.
    >> Share

  131. DENG Y, Huang W, Zeng T, Gao Y, et al
    CDK4/6 inhibitors combined with fulvestrant for the treatment of HR+/HER2-advanced or metastatic breast cancer: a Bayesian network meta-analysis.
    BMC Cancer. 2026 Feb 17. doi: 10.1186/s12885-026-15713.
    >> Share

  132. HOSSAIN I, Ivy SC, Islam MS, Shahriar M, et al
    Evaluation of ERCC4 (XPF) gene rs6498486 polymorphism and its potential role in breast cancer risk among Bangladeshi women.
    BMC Cancer. 2026 Feb 17. doi: 10.1186/s12885-026-15739.
    >> Share

  133. CONTRERAS-SANCHEZ SE, Doubova SV, Grajales-Alvarez R, Villalobos-Valencia R, et al
    Effectiveness of a digital health intervention on the supportive care needs and quality of life in Mexican patients with breast cancer: a randomized clinical trial.
    BMC Cancer. 2026 Feb 16. doi: 10.1186/s12885-026-15724.
    >> Share

  134. LIAO H, Li H, Qu Y, Tang L, et al
    IL-8 positive cancer-associated fibroblasts drive breast cancer progression and immune evasion: insights from GWAS and single-cell transcriptomics.
    BMC Cancer. 2026 Feb 16. doi: 10.1186/s12885-026-15716.
    >> Share

  135. AROMAA-HAYHA A, Auvinen P, Malila N, Kataja V, et al
    Nonadherence to changing guidelines in early breast cancer over two decades.
    BMC Cancer. 2026 Feb 16. doi: 10.1186/s12885-026-15731.
    >> Share

  136. EL-KHAZRAGY N, Alsolami A, Aref AM, Hassan MNM, et al
    MiR-200c restoration inhibits FOXP3 and metastatic spread in breast cancer: evidence from in vitro and in vivo models.
    BMC Cancer. 2026 Feb 14. doi: 10.1186/s12885-026-15574.
    >> Share

  137. ZHANG J, Dai C, Wang S, Chen Y, et al
    An evaluation model of chemotherapy efficacy in breast cancer based on combined serum CA15-3, CEA, and CYFRA 21 - 1.
    BMC Cancer. 2026 Feb 14. doi: 10.1186/s12885-026-15687.
    >> Share

  138. OKTEN IN, Baydas T, Koca S, Baltaci MF, et al
    Breast cancer surgery in the era of genetic uncertainty: real-world outcomes in BRCA1/2 pathogenic variants and variants of uncertain significance.
    BMC Cancer. 2026 Feb 13. doi: 10.1186/s12885-026-15721.
    >> Share

  139. GAO Y, Gong J, Yang Y, Luo Y, et al
    Stratified prediction of HER2 status in breast cancer by integrating intratumoral and peritumoral radiomics from DCE-MRI.
    BMC Cancer. 2026 Feb 13. doi: 10.1186/s12885-026-15688.
    >> Share

  140. KUBECZKO M, Polakiewicz-Gilowska A, Swiderska K, Mianowska-Malec M, et al
    Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors.
    BMC Cancer. 2026 Feb 13. doi: 10.1186/s12885-026-15594.
    >> Share

  141. MAYBERRY SA, Hsu PC, Lin HY, Rogers LJ, et al
    Association of DNA methyltransferase polymorphisms with breast cancer: a nested case?control study of the Arkansas Rural Community Health study.
    BMC Cancer. 2026 Feb 10. doi: 10.1186/s12885-026-15695.
    >> Share

  142. ZHANG L, Sun F, Wang X, Zhao W, et al
    Efficacy and safety of treatments in HR+/HER2- advanced breast cancer after CDK4/6 inhibitor progression: a network meta-analysis and scoping review.
    BMC Cancer. 2026 Feb 7. doi: 10.1186/s12885-026-15632.
    >> Share

  143. OZTURK HA, Koc M, Okyay RA, Ozturk DD, et al
    Cardioprotective effects of dapagliflozin against doxorubicin-induced cardiotoxicity in breast cancer patients with type 2 diabetes: a prospective study.
    BMC Cancer. 2026 Feb 7. doi: 10.1186/s12885-026-15696.
    >> Share

  144. LAMY C, Laurent L, Choussy O, Pouget N, et al
    SCANDARE: an institutional dynamic prospective interventional biobanking study.
    BMC Cancer. 2026;26:330.
    >> Share

  145. CAMPONE M, Frenel JS, Kiver VII, Woeckel A, et al
    Treatment patterns and clinical outcomes in chemotherapy-treated patients with HR+/HER2- metastatic breast cancer using real-world data in France and Germany.
    BMC Cancer. 2026 Feb 3. doi: 10.1186/s12885-026-15611.
    >> Share

    January 2026
  146. SAFAVI A, Mohammadzadeh N, Kaviani A, Dadashi A, et al
    Axillary staging in post-neoadjuvant chemotherapy breast cancer patients: prognostic analysis and validation of axillary nodal metrics and comparison of pathological node staging versus the lymph node ratio systems in a 169-case series.
    BMC Cancer. 2026 Jan 30. doi: 10.1186/s12885-026-15564.
    >> Share

  147. BRANDSTETTER LS, Grau A, Muller-Reiter M, Salmen J, et al
    Medication adherence in a German cohort of patients with advanced or metastatic breast cancer: results of the BRE-BY-MED study.
    BMC Cancer. 2026 Jan 30. doi: 10.1186/s12885-026-15641.
    >> Share

  148. TAO R, Liu B, Gao S, Zhang J, et al
    The role of CD26 in breast cancer and its pan-cancer analysis.
    BMC Cancer. 2026 Jan 30. doi: 10.1186/s12885-026-15656.
    >> Share

  149. WOOF VG, Howell A, Fox L, McWilliams L, et al
    How do women experience a change in their clinically-derived breast cancer risk estimates: views from a UK family history risk and prevention clinic.
    BMC Cancer. 2026 Jan 29. doi: 10.1186/s12885-026-15651.
    >> Share

  150. AWADA Z, Kazmi N, Jones HJ, Lewis SJ, et al
    The causal association between systolic blood pressure and breast cancer: a two sample Mendelian randomization study.
    BMC Cancer. 2026 Jan 22. doi: 10.1186/s12885-025-15513.
    >> Share

  151. FENG L, Liang Y, Huang J, Xu S, et al
    Evaluation of organs at risk (OARs) in whole-breast irradiation: a comparison of prone, supine position and with deep inspiration breath-hold techniques-subgroup analysis from a prospective study.
    BMC Cancer. 2026;26:307.
    >> Share

  152. CAZZANIGA ME, Galimberti S, Pepe FF, Cogliati V, et al
    Metronomic (mCHT) vs standard (sCHT) chemotherapy as first-line treatment in HR+/HER2- Metastatic Breast Cancer (MBC) patients following failure of endocrine treatments. The matched control VICTOR-15 study.
    BMC Cancer. 2026 Jan 20. doi: 10.1186/s12885-025-15482.
    >> Share

  153. AIKELAIMU A, Li W, Kaicaier M, Liu S, et al
    Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy in breast cancer: a systematic review and meta-analysis with focus on triple-negative subtype and immune-related adverse events.
    BMC Cancer. 2026 Jan 19. doi: 10.1186/s12885-025-15521.
    >> Share

  154. ELALFY E, Gaber NE, Helmy MH, Kamel MA, et al
    Scrutinizing the potential role of non-coding RNAs as biomarkers in Egyptian females with early and metastatic breast cancer.
    BMC Cancer. 2026 Jan 14. doi: 10.1186/s12885-025-15483.
    >> Share

  155. CHEKHUN V, Lukianova Y, Mushii O, Zadvornyi T, et al
    Breast cancer microenvironment composition associated with high PD-L1 expression.
    BMC Cancer. 2026 Jan 14. doi: 10.1186/s12885-026-15542.
    >> Share

  156. ZHANG C, Li S, Ren J, Wen X, et al
    Optimizing ribociclib dosing in breast cancer with brain metastasis patients using a physiologically based pharmacokinetic model.
    BMC Cancer. 2026 Jan 13. doi: 10.1186/s12885-026-15561.
    >> Share

  157. CHOUDHARY A, Poojary SS, Jain P, Chaturvedi H, et al
    Identification of novel exosomal miRNAs and their role in diagnosis and prognosis of triple negative breast cancer.
    BMC Cancer. 2026 Jan 13. doi: 10.1186/s12885-025-15499.
    >> Share

  158. SHI QF, Hu PF, Liu YH
    Ultrasound for predicting pathological response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2026 Jan 13. doi: 10.1186/s12885-026-15545.
    >> Share

  159. PETER M, Swaminathan N, Govindharaj P
    Development of culture specific quality of life tool for breast cancer survivors of Indian population.
    BMC Cancer. 2026 Jan 10. doi: 10.1186/s12885-026-15563.
    >> Share

  160. ADAMSON B, van Boemmel-Wegmann S, Horne E, Soares S, et al
    Real-world evidence from Germany: representativeness analysis and mortality endpoint validation in electronic health record-derived oncology cohorts.
    BMC Cancer. 2026;26:202.
    >> Share

  161. HUNDAL J, Williams D, Nock NL, Austin K, et al
    Older breast cancer survivors' exercise and support group program experiences and recommendations from the IMPROVE trial: a qualitative study.
    BMC Cancer. 2026 Jan 6. doi: 10.1186/s12885-025-15425.
    >> Share

  162. YOON TI, Baek S, Lee JH, Yoo TK, et al
    Clinical significance of peripheral blood parameters as a prognostic biomarker in patients receiving neoadjuvant chemotherapy for breast cancer.
    BMC Cancer. 2026 Jan 3. doi: 10.1186/s12885-025-15510.
    >> Share

    December 2025
  163. LV M, Liu Y, Cao W, Wang Y, et al
    Identification of RPGRIP1L as an instability-maintaining gene to drive tumor growth and PD-L1 expression via Hedgehog signaling in breast cancer.
    BMC Cancer. 2025 Dec 30. doi: 10.1186/s12885-025-15500.
    >> Share

  164. NAFISSI N, Rezazadeh M, Kheradpishe A, Radkhah H, et al
    Diagnostic value of peripheral blood inflammatory indices for breast cancer grade and immunohistochemical markers: a retrospective observational study.
    BMC Cancer. 2025;25:1886.
    >> Share

  165. WEI C, Zhou S, Zhu L, Kong J, et al
    Comparison of the efficacy between radiotherapy alone and surgery plus radiotherapy for ipsilateral supraclavicular lymph node metastasis in breast cancer based on propensity score matching analysis: a retrospective study with 8-year follow-up.
    BMC Cancer. 2025 Dec 26. doi: 10.1186/s12885-025-15424.
    >> Share

  166. CHEN BA, Qin WH, Chen HB, Yang QH, et al
    The effect of exercise intervention on IGF axis and metabolic markers regulation in breast cancer patients: a systematic review with pairwise, network, and dose-response meta-analyses.
    BMC Cancer. 2025 Dec 26. doi: 10.1186/s12885-025-15475.
    >> Share

  167. MASHAYEKH Z, Fard RF, Vallian S
    Noncoding RNAs and DNA methylation as epigenetic modulators of breast cancer: mechanisms and clinical perspectives in the Iranian population, a systematic review.
    BMC Cancer. 2025 Dec 20. doi: 10.1186/s12885-025-15430.
    >> Share

  168. ALHALABI A, Abdo T, Hijazi A, Mohanna M, et al
    Factors associated with developing and surviving brain metastases in patients with breast cancer: a multi-center experience.
    BMC Cancer. 2025 Dec 19. doi: 10.1186/s12885-025-15422.
    >> Share

  169. HEIDINGER M, Staehelin S, Halbeisen FS, Maggi N, et al
    Impact of bilateral surgery on time to treatment in patients with breast cancer undergoing mastectomy - a retrospective cohort study.
    BMC Cancer. 2025 Dec 19. doi: 10.1186/s12885-025-15389.
    >> Share

  170. XIE H, Zhang J, Li Q, Tan T, et al
    Enhancing breast cancer diagnosis: non-invasive prediction of MKI-67 (Ki67) expression using ultrasound images.
    BMC Cancer. 2025 Dec 15. doi: 10.1186/s12885-025-15443.
    >> Share

  171. YILMAZ S, Yur M
    CA 15 - 3 may be a promising biomarker for differentiating distant organ metastasis in breast cancer at initial diagnosis.
    BMC Cancer. 2025 Dec 15. doi: 10.1186/s12885-025-15463.
    >> Share

  172. ANDRADE DC, Parrish L, Harriss C, Peterson LL, et al
    A qualitative exploration of patient and clinician needs and preferences for a physical activity intervention during breast cancer chemotherapy.
    BMC Cancer. 2025 Dec 12. doi: 10.1186/s12885-025-15342.
    >> Share

  173. FESSI Z, Bonnier S, Lodyga K, Wallet J, et al
    Stereotactic re-irradiation for lymph node recurrence of breast cancer.
    BMC Cancer. 2025 Dec 8. doi: 10.1186/s12885-025-15418.
    >> Share

  174. HUANG H, Chen X, Wang Z, Zhang Y, et al
    Evidence-based prescription: optimal exercise type and dose for pain management in breast cancer survivors-a systematic review and dose-response network meta-analysis.
    BMC Cancer. 2025 Dec 6. doi: 10.1186/s12885-025-15432.
    >> Share

  175. YANG Y, Ma Y, Xue F, Li J, et al
    Using single-cell and transcriptome data to identify prognostic genes associated with SUMO-ylation and their molecular regulatory mechanisms in breast cancer.
    BMC Cancer. 2025 Dec 6. doi: 10.1186/s12885-025-15265.
    >> Share

  176. ALLSOPP RC, Page K, Wren E, Nteliopoulos G, et al
    Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
    BMC Cancer. 2025;25:1858.
    >> Share

  177. CAGDAS EK, Cagdas B
    LYN mutations in breast cancer: hypothesis-generating evidence for an association with central nervous system metastasis and domain-level insights.
    BMC Cancer. 2025 Dec 5. doi: 10.1186/s12885-025-15398.
    >> Share

  178. DA COSTA NC, Fernandes ACP, Damin APS
    Prognostic relevance of increased tumor-infiltrating lymphocytes in residual TNBC following neoadjuvant chemotherapy.
    BMC Cancer. 2025;25:1856.
    >> Share

  179. LI X, Li C, Jiang L, Zheng D, et al
    Automated machine learning-based unenhanced radiomics for identification of HER2-low breast cancers using diffusion-weighted imaging.
    BMC Cancer. 2025;26:66.
    >> Share

  180. SARFRAZ Z, Ozair A, Bardhan M, Starosciak AK, et al
    Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): Study protocol for a multicenter phase 1 clinical trial.
    BMC Cancer. 2025 Dec 4. doi: 10.1186/s12885-025-15224.
    >> Share

  181. SPERK E, Lemanski C, Neumaier C, Lauer J, et al
    Intraoperative radiotherapy in elderly patients with breast cancer: long-term follow-up results of the prospective phase II trial TARGIT-E.
    BMC Cancer. 2025;25:1862.
    >> Share

  182. JENKINSON NM, Hughes S, Baras A, Meeker A, et al
    Context-dependent MAN1A1 protein expression in metastatic breast cancer progression predicts patient survival.
    BMC Cancer. 2025 Dec 1. doi: 10.1186/s12885-025-15380.
    >> Share

  183. DU R, Qian R, Qin R, Yu Y, et al
    Gradient perfusion features can effectively identify sentinel lymph node metastasis in early breast cancer.
    BMC Cancer. 2025 Dec 1. doi: 10.1186/s12885-025-15251.
    >> Share

  184. PETER J, Jolly B, Raha R, Jothi J, et al
    Germline mutational landscape in a large cohort of Indian breast cancer.
    BMC Cancer. 2025 Dec 1. doi: 10.1186/s12885-025-15360.
    >> Share

    November 2025
  185. LIU C, Wang R, Wang S, Liu S, et al
    Pregnancy-associated breast cancer: gestational weight gain impact and nomogram validation.
    BMC Cancer. 2025 Nov 29. doi: 10.1186/s12885-025-15292.
    >> Share

  186. RANTALA J, Seppa K, Eriksson J, Heinavaara S, et al
    Associations between modifiable factors and early-onset breast cancer mortality among patients.
    BMC Cancer. 2025 Nov 29. doi: 10.1186/s12885-025-15226.
    >> Share

  187. BAS O, Inci BK, Eroglu I, Efil SC, et al
    Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience.
    BMC Cancer. 2025;25:1831.
    >> Share

  188. HAFEEZ A, Basit M, Zafar S, Shabbir M, et al
    Comprehensive analysis of gene expression alterations in breast cancer patients via PKCtheta-TBK1-mTORC1 signaling pathway.
    BMC Cancer. 2025;25:1844.
    >> Share

  189. TAKADA K, Kashiwagi S, Nishikawa M, Kochi A, et al
    Clinical characteristics and prognostic impact of HER2-ultralow breast cancer and tumor-infiltrating lymphocytes (TILs).
    BMC Cancer. 2025 Nov 28. doi: 10.1186/s12885-025-15255.
    >> Share

  190. KITONGO E, Segawa ES, Joyce N, Valeria N, et al
    Mammographic findings and BI-RADS concordance in women attending a community outreach program in Uganda.
    BMC Cancer. 2025;26:15.
    >> Share

  191. MARICIC VRBAN M, Radovani Trbojevic B, Visentin D, Ramljak K, et al
    Therapy-induced remodeling of IgG and plasma N-glycans in breast cancer.
    BMC Cancer. 2025 Nov 27. doi: 10.1186/s12885-025-15381.
    >> Share

  192. LI J, Liu J, Cai B, Yang C, et al
    Association of estimated glucose disposal rate with all-cause and breast cancer-specific mortality in US breast cancer survivors: a population-based study.
    BMC Cancer. 2025 Nov 27. doi: 10.1186/s12885-025-15340.
    >> Share

  193. PINCHAS-MIZRACHI R, Bouhnik D
    Correction: The parity paradox: does number of children (parity) influence breast cancer mortality across the life course?
    BMC Cancer. 2025;25:1830.
    >> Share

  194. SPERLICH S, Geyer S, Holthausen-Markou S, Park-Simon TW, et al
    Breast cancer survivors' participation in social activities five years after primary surgery - are there social inequalities?
    BMC Cancer. 2025;25:1829.
    >> Share

  195. COELHO LL, Vianna MM, da Silva DM, Gonzaga BMS, et al
    beta-lapachone impairs viability, migration, and epithelial-mesenchymal transition in mammary tumor spheroids.
    BMC Cancer. 2025;25:1826.
    >> Share

  196. DENG Z, Li Y, Luo Y, Cao X, et al
    Nomogram models for prediction of axillary lymph node metastasis in breast cancer patients.
    BMC Cancer. 2025;25:1827.
    >> Share

  197. YUAN S, Li J, Liu W, Ren M, et al
    CLIC3 emerges as a novel prognostic biomarker and therapeutic target in triple-negative breast cancer through integrated multi-omics analysis.
    BMC Cancer. 2025;25:1828.
    >> Share

  198. SALARI Z, Khosravi A, Riahi A, Molaakbari E, et al
    Niosomal mefloquine and cisplatin in breast cancer: comparative effects on apoptosis and angiogenesis via in vitro and in silico analysis.
    BMC Cancer. 2025 Nov 26. doi: 10.1186/s12885-025-15372.
    >> Share

  199. WU F, Xu F, He J, Hu H, et al
    Reducing breast biopsy at MRI: comparison of minimum ADC cutoff and mean ADC cutoff identified by the ECOG-ACRIN A6702 multicenter trial.
    BMC Cancer. 2025;25:1938.
    >> Share

  200. MALAWARAARACHCHI BP, Abeysinghe C, Seneviwickrama M, Ranasinghe S, et al
    Body image concerns among women diagnosed with breast cancer in a South Asian setting: a phenomenology approach.
    BMC Cancer. 2025;25:1819.
    >> Share

  201. OJEDELE OA, Hamdi N, Mughram MHA, Alyami EM, et al
    Identification of potential novel aromatase inhibitors as therapeutic strategies against breast cancer: insight into molecular docking, MD simulations and ADMET profiling.
    BMC Cancer. 2025;25:1812.
    >> Share

  202. GERSHFELD-LITVIN A, Shay-Peretz N, Hanalis-Miller T
    Motherhood with HBOC in Israel: experiencing preventive disruption.
    BMC Cancer. 2025;25:1928.
    >> Share

  203. LYU Q, Yuan H, Lin Z, Barcus R, et al
    A large scale multi-dataset investigation of brain metastases distribution based on primary cancer type.
    BMC Cancer. 2025;25:1821.
    >> Share

  204. ZHANG H, Yin X, Wang S, Li Q, et al
    Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer.
    BMC Cancer. 2025;25:1806.
    >> Share

  205. YAN X, Zhang X, Wang Z, Yang L, et al
    Safety and efficacy of immune checkpoint inhibitors in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:1804.
    >> Share

  206. SENDUR MAN, Hizal M, Cakar B, Aktepe OH, et al
    Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program.
    BMC Cancer. 2025 Nov 22. doi: 10.1186/s12885-025-15287.
    >> Share

  207. DELABY C, Al Herk A, Hirtz C, Jacot W, et al
    Hepcidin as an emerging predictor biomarker of leptomeningeal metastases in patients with metastatic breast cancer.
    BMC Cancer. 2025;25:1801.
    >> Share

  208. SHAWANA S, Mirza T, Khatoon A, Mushtaq S, et al
    Uncovering rare somatic variants in olfactory receptor genes in Pakistani triple-negative breast cancer patients.
    BMC Cancer. 2025;25:1799.
    >> Share

  209. WANG A, Zeng P, Ma T, Shi H, et al
    Establishment of a new method for detection of TROP2-positive circulating tumor cells in breast cancer.
    BMC Cancer. 2025;25:1797.
    >> Share

  210. YU S, Wu J
    CTHRC1-driven breast cancer progression: insights from palmitoylation networks and spatial heterogeneity.
    BMC Cancer. 2025;25:1795.
    >> Share

  211. CHEN Q, Xiong J, Wang H, Xu Y, et al
    A nomogram for breast cancer brain metastasis patients after stereotactic radiotherapy.
    BMC Cancer. 2025;25:1784.
    >> Share

  212. FANG Q, Sanderson RW, Zilkens R, Boman I, et al
    Diagnostic feasibility study of stereoscopic optical palpation for breast tumour margin assessment.
    BMC Cancer. 2025;25:1793.
    >> Share

  213. LOZA P, Irmejs A, Daneberga Z, Maksimenko J, et al
    The difference in contralateral breast cancer and ovarian cancer risks for BRCA1 founder variant (c.5266dup, c.4035del) carriers with primary breast cancer.
    BMC Cancer. 2025;25:1769.
    >> Share

  214. ZHANG Y, Cai J, Cui C, Qi S, et al
    Predicting breast cancer response to neoadjuvant therapy by integrating radiomic and deep-learning features from early-and-peak phases of DCE-MRI.
    BMC Cancer. 2025;25:1747.
    >> Share

  215. MIZRACHI RP, Bouhnik D
    The parity paradox: does number of children (parity) influence breast cancer mortality across the life course?
    BMC Cancer. 2025;25:1750.
    >> Share

  216. MONKAM P, Wang X, Zhao B, Qi S, et al
    Efficient temporal feature utilization in ultrasound videos: a multi-channel deep learning framework for enhanced breast lesion differentiation.
    BMC Cancer. 2025;25:1744.
    >> Share

  217. SECA M, Gronwald J, Huzarski T, Glass K, et al
    Treatment of infertility and risk of breast cancer among women with a BRCA pathogenic variant: a matched case-control study.
    BMC Cancer. 2025;25:1740.
    >> Share

  218. LIU J, Leng X, Yuan Z, Li Y, et al
    Predicting breast cancer response to neoadjuvant chemotherapy with ultrasound-based deep learning radiomics models -- dual-center study.
    BMC Cancer. 2025;25:1737.
    >> Share

  219. VENGHATERI JB, Nathani P, Goyal S, Sarang B, et al
    Low participation in cancer screening in India: a scoping review of breast and cervical cancer programs.
    BMC Cancer. 2025;25:1724.
    >> Share

  220. OSHINO T, Shimizu H, Sato M, Nishida M, et al
    Impact of breast tumor size discrepancy between contrast-enhanced and conventional ultrasonography on axillary node metastasis: a retrospective cohort study.
    BMC Cancer. 2025;25:1718.
    >> Share

  221. TOKUR O, Aydin S, Kilinc F, Degirmenci T, et al
    Diagnostic value of super microvascular imaging in differentiating axillary lymph nodes: semi-quantitative and qualitative approach in primary breast cancer and suspicious axillary nodes.
    BMC Cancer. 2025;25:1705.
    >> Share

  222. IMAMURA S, Mori K, Yasojima H, Mizutani M, et al
    Genomically determined subtypes and clinicopathological features as predictors of the efficacy of preoperative chemotherapy combined with HER2-targeted therapy for early-stage HER2-positive breast cancer.
    BMC Cancer. 2025;25:1707.
    >> Share

    October 2025
  223. ELSNER SA, Haussmann E, Grieger P, Hadwiger M, et al
    Optimising breast cancer screening in national mammography screening centres: challenges and insights on implementing additional ultrasound for women with dense breast tissue - a qualitative study.
    BMC Cancer. 2025;25:1684.
    >> Share

  224. ZAFAR S, Badshah Y, Shabbir M, Khan S, et al
    Comprehensive computational analysis of PKCdelta non-synonymous variants identifies rs1703863535 as a potential breast cancer biomarker.
    BMC Cancer. 2025;25:1667.
    >> Share

  225. TOMCZIK K, Niznik J, Coombs LA
    "Who's gonna take care of my babies?" the impact of children on treatment decisions for women with metastatic breast cancer: a qualitative analysis.
    BMC Cancer. 2025;25:1662.
    >> Share

  226. RE F, Manaboriboon N, Raza IGA, Shipley A, et al
    A systematic review of prediction models for risk of breast cancer.
    BMC Cancer. 2025;25:1650.
    >> Share

  227. AMIN A, U DA, Koteshwara P, P C S, et al
    A systematic literature review on mammography: deep learning techniques for breast cancer detection with global and Asian perspectives.
    BMC Cancer. 2025;25:1627.
    >> Share

  228. SONG Z, Ding M, Zang Q, Wang L, et al
    Association of reproductive and menstrual factors with the risk of breast cancer in women: a population-based study.
    BMC Cancer. 2025;25:1621.
    >> Share

  229. DERISMAHAFI Z, Farhud D, Razavirad A, Muhammadnejad A, et al
    NRF2 expression level and estrogen function in BRCA1-mutated breast cancer.
    BMC Cancer. 2025;25:1622.
    >> Share

  230. LI Y, Zhang Z, Liu X, Cheng Y, et al
    Integrative analysis identifies radiotherapy resistance-associated CAF subtypes shaping the tumor immune landscape in breast cancer.
    BMC Cancer. 2025;25:1603.
    >> Share

  231. GUO X, Gong X, Yang Y, Wang L, et al
    Circumferential periareolar incision length as a risk factor for skin necrosis after nipple-sparing mastectomy with deep inferior epigastric perforator flap reconstruction.
    BMC Cancer. 2025;25:1592.
    >> Share

  232. LI Y, Long X, Xie Y, Zhong X, et al
    Tropomodulin 1 is essential for chemotherapy sensitivity and associated with better outcome in triple-negative breast cancer.
    BMC Cancer. 2025;25:1594.
    >> Share

  233. SHARMA A, Johnson KB, Sen A, Bie B, et al
    Longitudinal multi-omics analyses of chemotherapy-induced peripheral neuropathy in response to taxanes.
    BMC Cancer. 2025;25:1591.
    >> Share

  234. LI L, Yang P, Hong C, Chen D, et al
    Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response and prognosis in breast cancer: a multicenter retrospective study based on Chinese population.
    BMC Cancer. 2025;25:1585.
    >> Share

  235. YAO G, Huang Y, Shang X, Guo L, et al
    Prediction of intraductal cancer microinfiltration based on the hierarchical fusion of peri-tumor imaging histology and dual view deep learning.
    BMC Cancer. 2025;25:1564.
    >> Share

  236. OKAZAKI M, Ueda A, Iguchi-Manaka A, Mathis BJ, et al
    Refining compression therapy for the prevention of chemotherapy-induced peripheral neuropathy in breast cancer patients: a sub-analysis of patient-reported discomfort and usability.
    BMC Cancer. 2025;25:1567.
    >> Share

  237. COSTA-PEREIRA JP, Macedo IF, Barbosa GA, Leitao GM, et al
    Myosteatosis is associated with advanced TNM stage and tumor features in young females with breast cancer.
    BMC Cancer. 2025;25:1576.
    >> Share

  238. SCHAGERHOLM STANEV C, Sifakis EG, Hases L, Chen X, et al
    Transcriptomic profiles of endocrine-resistant breast cancer.
    BMC Cancer. 2025;25:1556.
    >> Share

  239. SIMONYAN RM, Babayan MA, Yekmalyan HH, Simonyan SG, et al
    Thermostable enzyme isoforms, continuously producing monocomponent superoxide radicals, from human postoperative serous fluids: isolation and properties.
    BMC Cancer. 2025;25:1555.
    >> Share

  240. FATHIMA ZS, Suresh TNR, Kattepur AK
    Immunohistochemical expression of tumor-infiltrating lymphocytes CD8 and FOXP3 in invasive ductal carcinoma of breast.
    BMC Cancer. 2025;25:1550.
    >> Share

  241. LIU Y, Ren T, Chen X, He Q, et al
    Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HR2- patients with advanced or metastatic breast cancer: a systematic review and network meta-analysis.
    BMC Cancer. 2025;25:1535.
    >> Share

  242. TAKADA K, Kashiwagi S, Nishikawa M, Kochi A, et al
    Differences in Sentinel lymph node biopsy outcomes and prognosis between HER2-low and HER2-zero breast cancer.
    BMC Cancer. 2025;25:1518.
    >> Share

  243. VARGHESE D, Collins J, Nordstrom B, Miranda M, et al
    Epidemiology and outcomes associated with brain metastases among patients with metastatic breast cancer - a cohort study in US electronic health record data.
    BMC Cancer. 2025;25:1475.
    >> Share

  244. HOSSEINI SS, Askari N, Yaghoobi MM
    Combined anti-tumor effects of metformin and azacitidine in breast cancer cells.
    BMC Cancer. 2025;25:1487.
    >> Share

  245. AFAYA A, Lee H, Kim SY, Park CG, et al
    Multilevel factors associated with clinical breast examination uptake among women in the Northern Region of Ghana: a cross-sectional survey.
    BMC Cancer. 2025;25:1476.
    >> Share

  246. KORANTZIS I, Koumarianou A, Rapti V, Timotheadou E, et al
    Real-world management strategies and clinical outcomes of metastatic HER2-positive breast cancer in Greece in the second-line setting and beyond (the togetHER study).
    BMC Cancer. 2025;25:1473.
    >> Share

    September 2025
  247. AL-TAJ MA
    Sweets consumption and breast cancer risk among women in yemen: a matched case control study.
    BMC Cancer. 2025;25:1495.
    >> Share

  248. WYATT LC, Nguyen CH, LeCroy MN, Foster V, et al
    Prevalence of breast, cervical, and colorectal cancer screenings among select New York City populations.
    BMC Cancer. 2025;25:1469.
    >> Share

  249. CHEN X, Cheng Z, Li Y, Wu X, et al
    Development and validation of a machine learning model to predict delays in seeking medical care among patients with breast cancer in China.
    BMC Cancer. 2025;25:1442.
    >> Share

  250. ZHOU J, Liang B, Su M, Zhang Z, et al
    Long-term exposures to PM(2.5) components increase the breast cancer mortality in the region of Inner Mongolia, China: a retrospective study based on mixture cure model.
    BMC Cancer. 2025;25:1465.
    >> Share

  251. DURRANI S, Al-Ghamdi AA, Al-Bugawi A, Al-Khammash A, et al
    Prognostic factors and survival outcome of brain metastases in breast cancer patients: a retrospective analysis.
    BMC Cancer. 2025;25:1455.
    >> Share

  252. YAHYAPOUR A, Askari N, Yaghoobi MM
    Combination of hydralazine and all-trans retinoic acid targeting breast cancer cells.
    BMC Cancer. 2025;25:1427.
    >> Share

  253. JANG MK, Park S, Jeon JY, Kang MJ, et al
    Correction: Evaluating the effects of a resistance exercise intervention for sarcopenia in patients receiving neoadjuvant chemotherapy for breast cancer: study protocol for a randomized controlled trial.
    BMC Cancer. 2025;25:1422.
    >> Share

    August 2025
  254. YANG Y, Zhao Y, Yao K, Li W, et al
    The influence of cancer treatments on long-term psychological outcomes and quality of life in breast cancer patients.
    BMC Cancer. 2025;25:1403.
    >> Share

  255. KURANT DE, Groha S, Ding Y, German C, et al
    Association between polygenic risk and survival in breast cancer patients.
    BMC Cancer. 2025;25:1393.
    >> Share

  256. LI JD, Deng LL, Luo JY, Mo CH, et al
    The role of collagen type VI alpha 6 chain as a potential tumor suppressor in breast cancer: an immune regulation perspective.
    BMC Cancer. 2025;25:1363.
    >> Share

  257. ARAUJO CFM, Nunes LC, Murta-Nascimento C, Bragagnoli AC, et al
    Metformin for the treatment of breast cancer: a scoping review of randomized clinical trials.
    BMC Cancer. 2025;25:1352.
    >> Share

  258. WANG Y, Wang L, Yu B, Wen S, et al
    Global, regional, and national burden of male breast cancer and predictions in the next 30 years: a systematic analysis of the global burden of disease study 2021.
    BMC Cancer. 2025;25:1344.
    >> Share

  259. LIAN W, Li L, Hong C, Chen D, et al
    Impact of ovarian function suppression on prognosis in premenopausal patients with HR+/HER2 + early-stage breast cancer: a multi-center retrospective study.
    BMC Cancer. 2025;25:1331.
    >> Share

  260. SREENATH ND, Pandalanghat S, Kapoor A, Govind R, et al
    A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort.
    BMC Cancer. 2025;25:1337.
    >> Share

  261. TAIWO R, Harary PM, Trinh TTH, Granucci M, et al
    Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases.
    BMC Cancer. 2025;25:1316.
    >> Share

  262. LI SY, Li YM, Fang YQ, Jin ZY, et al
    Contrast-enhanced ultrasound radiomics model for predicting axillary lymph node metastasis and prognosis in breast cancer: a multicenter study.
    BMC Cancer. 2025;25:1315.
    >> Share

  263. QIN JN, Dai WB, Zhang WH, Chen BJ, et al
    Identification of optimal biomarkers associated with distant metastasis in breast cancer using Boruta and Lasso machine learning algorithms.
    BMC Cancer. 2025;25:1311.
    >> Share

  264. MARIOSA D, Ponzano M, Grotta A, Lagerros YT, et al
    Dietary non-enzymatic antioxidant capacity and risk of breast cancer: the Swedish National March Cohort.
    BMC Cancer. 2025;25:1310.
    >> Share

  265. FU J, Deng S, Zheng W, Zheng C, et al
    Construction of a transfer learning-based depression detection model for female breast cancer patients: text sentiment analysis.
    BMC Cancer. 2025;25:1307.
    >> Share

  266. XING B, Gu C, Fu C, Zhang B, et al
    Diagnostic performance of ultrasound S-Detect technology in evaluating BI-RADS-4 breast nodules 20 mm.
    BMC Cancer. 2025;25:1306.
    >> Share

  267. LEE J, Ahn HK, Lee KH, Jung KH, et al
    Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemother
    BMC Cancer. 2025;25:1295.
    >> Share

  268. JANG MK, Park S, Jeon JY, Kang MJ, et al
    Evaluating the effects of a resistance exercise intervention for sarcopenia in patients receiving neoadjuvant chemotherapy for breast cancer: study protocol for a randomized controlled trial.
    BMC Cancer. 2025;25:1296.
    >> Share

  269. OLSON R, Cua M, Matthews Q, Laing J, et al
    Phase II single vs hypofractionated irradiation for timely access to partial breast radiotherapy (SHIFT-PB).
    BMC Cancer. 2025;25:1285.
    >> Share

  270. SAROOSH R, Ahmad N, Israr B, Nazir A, et al
    Association of diabetes mellitus and breast cancer in adult men and women: a cross-sectional survey.
    BMC Cancer. 2025;25:1276.
    >> Share

  271. TAFESE AM, Fentie MT, Seifu BL, Asnake AA, et al
    Breast cancer survival rates and determinants in Ethiopia: a systematic review and meta-analysis of longitudinal studies.
    BMC Cancer. 2025;25:1263.
    >> Share

  272. AL-MASRI M, Aljalabneh B, AlMasri R, Alayyan O, et al
    Comparative survival analysis of HER2-positive Pregnancy-Associated Breast Cancer (PABC) and non-Pregnancy-Associated breast Cancer (non-PABC) cohorts: a matched control study.
    BMC Cancer. 2025;25:1252.
    >> Share

    July 2025
  273. LUO L, Zhang X, Chen L, Chen Z, et al
    Dual-targeting and steric hindrance resolution in HER2 IHC: a novel approach to improve diagnostic sensitivity.
    BMC Cancer. 2025;25:1231.
    >> Share

  274. WANG W, Wu B, Li J, Shang Y, et al
    The application and predictive value of the weight-adjusted-waist index in BC prevalence assessment: a comprehensive statistical and machine learning analysis using NHANES data.
    BMC Cancer. 2025;25:1234.
    >> Share

  275. SHARIATMADARI H, Taheri-Kharameh Z, Kamaliuon N, Ghanbari Hashem Abadi BA, et al
    Comparing the effectiveness of gratitude intervention and behavioral activation technique in breast cancer patients: a randomized trial.
    BMC Cancer. 2025;25:1226.
    >> Share

  276. SUN Q, Hu J, Ye Y, Ma L, et al
    The effect of smoking on breast cancer screening results in female population: a study in Wu wei, China.
    BMC Cancer. 2025;25:1225.
    >> Share

  277. EKDAHL HJELM T, Gebremariam TY, Weldearegay MF, Sori M, et al
    Stage at diagnosis and tumor characteristics among young women and men with breast cancer, in Ethiopia and Sweden, a descriptive cross-sectional study.
    BMC Cancer. 2025;25:1222.
    >> Share

  278. CHAI C, Shao K, Shan G, Li P, et al
    Dosimetric study of TrueBeam single-isocenter vs. Halcyon dual-isocenter VMAT radiotherapy plans for postoperative left-sided breast cancer.
    BMC Cancer. 2025;25:1214.
    >> Share

  279. ZHOU X, Wang Y, Xu Q, Ao X, et al
    BALs are prognostic biomarkers and correlate with malignant behaviors in breast cancer.
    BMC Cancer. 2025;25:1205.
    >> Share

  280. KING J, Fakhouri W, Jarvis R, Badreldin W, et al
    Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study.
    BMC Cancer. 2025;25:1189.
    >> Share

  281. NASIR J, Han B, Hu X, Ling H, et al
    Retrospective insights: clinical characteristics and survival in 403 ILC cases from China.
    BMC Cancer. 2025;25:1188.
    >> Share

  282. YANG L, Li Y, Zeng T, Long M, et al
    Gene mutation in cancer patients with diabetes: a real-world retrospective cohort study.
    BMC Cancer. 2025;25:1163.
    >> Share

  283. WANG S, Liu J, Song L, Zhao H, et al
    Integrative multimodal ultrasound and radiomics for early prediction of neoadjuvant therapy response in breast cancer: a clinical study.
    BMC Cancer. 2025;25:1156.
    >> Share

  284. LLEVENES P, Chen A, Lawton M, Rondon-Ortiz AN, et al
    Plasma exosomes in insulin resistant obesity exacerbate progression of triple negative breast cancer.
    BMC Cancer. 2025;25:1089.
    >> Share

  285. MOHEBBI A, Asli F, Mohammadzadeh S, Ardakani AA, et al
    Exploring the role of tumor to background parenchymal ratio of the [18F]FLT PET/CT measures in determining response to neoadjuvant chemotherapy in breast cancer: a multicenter study.
    BMC Cancer. 2025;25:1139.
    >> Share

  286. OSBORNE A
    Sex-disaggregated analysis of breast cancer prevalence in Sierra Leone.
    BMC Cancer. 2025;25:1022.
    >> Share

  287. HENDY A, Ibrahim RK, Darwish A, Al Sabbah S, et al
    Sleep disturbance, cancer-related fatigue, and depression as determinants of quality of life among breast cancer patients undergoing chemotherapy: a cross-sectional study.
    BMC Cancer. 2025;25:1122.
    >> Share

  288. DANG C, Wang R, Shi Y, Liu P, et al
    Genetically proxied therapeutic effect of antihypertensive drug use, breast cancer, and ovarian cancer's risk: a drug-target Mendelian randomization study.
    BMC Cancer. 2025;25:1125.
    >> Share

  289. GUO Q, Wu P, He J, Zhang G, et al
    Machine learning algorithms predict breast cancer incidence risk: a data-driven retrospective study based on biochemical biomarkers.
    BMC Cancer. 2025;25:1061.
    >> Share

  290. LU Z, Yang J, Feng Y, Ming J, et al
    Integrated proteomics and transcriptomics analysis reveals key regulatory genes between ER-positive/PR-positive and ER-positive/PR-negative breast cancer.
    BMC Cancer. 2025;25:1048.
    >> Share

  291. CHEANG I, Gue Y, Wu MZ, Huang JY, et al
    Cardiovascular risks associated with adjuvant endocrine therapy in women with breast cancer: a population-based cohort study.
    BMC Cancer. 2025;25:1063.
    >> Share

  292. LIAN J, Yao R, Xu Y, Tan L, et al
    Prediction of the 70-gene signature (MammaPrint) high versus low risk by nomograms among axillary lymph node positive (LN+) and negative (LN-) Chinese breast cancer patients, a retrospective study.
    BMC Cancer. 2025;25:1128.
    >> Share

  293. WANG C, Xiao D, Zhai C
    Efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.
    BMC Cancer. 2025;25:1072.
    >> Share

  294. SALLAUKA R, Horvat M, Ravnik M, Rashwan H, et al
    Scoping review: (Bio)markers for the prognostication of breast cancer recurrence.
    BMC Cancer. 2025;25:1081.
    >> Share

  295. ANWAR E, Amjad A, Zubairi AJ, Ali MM, et al
    De Novo bone metastasis in breast cancer: tumor biology and survival outcomes in a retrospective study from Pakistan.
    BMC Cancer. 2025;25:1074.
    >> Share

  296. CIVIL YA, Duvivier KM, Bartels SAL, Velde SV, et al
    Impact of neoadjuvant systemic therapy on surgical and radiotherapy outcomes in patients with early-stage breast cancer: a cross-sectional retrospective single-center study.
    BMC Cancer. 2025;25:1046.
    >> Share

  297. DEBELA MB, Gonfa KB, Hussen MM, Zenbaba D, et al
    Breast cancer determinants in low- to upper-middle-income countries: an umbrella review of meta-analyses of observational studies and an urgent call for implementation science.
    BMC Cancer. 2025;25:1096.
    >> Share

  298. CAREW JW, Radulescu SC, Zhang L, Ungurean C, et al
    Breast cancer mortality in Romania: trends, regional and rural-urban inequalities, and policy implications.
    BMC Cancer. 2025;25:1038.
    >> Share

  299. HAFEEZ A, Shabbir M, Badshah Y, Farooq A, et al
    Association of PRKCQ variants with breast cancer susceptibility and clinicopathological features.
    BMC Cancer. 2025;25:1069.
    >> Share

  300. ZENG Y, Liu R, Rong L
    Predictive value of androgen receptor in distant metastasis of triple-negative breast cancer: a retrospective multi-center study.
    BMC Cancer. 2025;25:1115.
    >> Share

  301. MARTI-DIAZ R, Sanchez-Del-Campo L, Montenegro MF, Hernandez-Caselles T, et al
    Ex vivo engineering of phagocytic signals in breast cancer cells for a whole tumor cell-based vaccine.
    BMC Cancer. 2025;25:1029.
    >> Share

  302. SHIAU JP, Yang CW, Liu W, Yu SY, et al
    Excavatolide C has oxidative-stress-dependent antiproliferative and apoptotic effects against breast cancer cells.
    BMC Cancer. 2025;25:1023.
    >> Share

  303. COSTANZO S, Godino L, De Summa S, Marvulli TM, et al
    BRCA cascade counselling and testing in Italy: current position and future directions.
    BMC Cancer. 2025;25:1044.
    >> Share

    June 2025
  304. WANG W, Sun Y, Li J, Bai H, et al
    Global, regional, and national burden of breast cancer in young women from 1990 to 2021: findings from the global burden of disease study 2021.
    BMC Cancer. 2025;25:1015.
    >> Share

  305. EBRAHIM NAA, Hussein MA, Sobeih ME, Amin NH, et al
    From biomarker to targeted therapy: investigating trophoblast cell-surface antigen 2 expression in triple-negative breast cancer- insights from the national cancer institute.
    BMC Cancer. 2025;25:1008.
    >> Share

  306. EL-JAMMAL M, Saifi O, Bazan J, Zeidan YH, et al
    Radiation therapy in clinically node positive HER2 positive breast cancer after primary systemic therapy and breast conserving surgery: pooled analysis of TRYPHAENA and NeoSphere trials.
    BMC Cancer. 2025;25:996.
    >> Share

  307. KARIMI MA, Khadem R, Haraj A, Farahani MA, et al
    The impact of sodium-glucose cotransporter-2 inhibitors on breast cancer and cancer-related mortality: a systematic review and meta-analysis of randomized controlled trials.
    BMC Cancer. 2025;25:991.
    >> Share

  308. OSBORNE A, Adnani QES, Ahinkorah BO
    Breast cancer incidence in Indonesia: a sex-disaggregated analysis using WHO health equity assessment toolkit data.
    BMC Cancer. 2025;25:986.
    >> Share

  309. LIANG Y, Xu H, Lin J, Tang W, et al
    Multi-modal radiomics model based on four imaging modalities for predicting pathological complete response to neoadjuvant treatment in breast cancer.
    BMC Cancer. 2025;25:985.
    >> Share

  310. BREEK K, Abuhalima D, Salameh H, Al-Jabi SW, et al
    Self-reported side effects of breast cancer treatment and its impact on quality of life: a multicenter cross-sectional study in a low- and middle-income country.
    BMC Cancer. 2025;25:975.
    >> Share

  311. AL-MATRAFI AR, Bedair KF, Srinivasan S, Palmer C, et al
    Clinical and pharmacogenomic predictors of survival in tamoxifen treated breast cancer female patients: a real-world study.
    BMC Cancer. 2025;25:974.
    >> Share

  312. GOERG A, Piendl G, Albert V, Ortmann O, et al
    Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition.
    BMC Cancer. 2025;25:978.
    >> Share

    May 2025
  313. WANG C, Chen J, Lv X, Yun T, et al
    Ki-67-Playing a key role in breast cancer but difficult to apply precisely in the real world.
    BMC Cancer. 2025;25:962.
    >> Share

  314. YANG B, Sun Z, Ouyang Q, Tong Z, et al
    Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China.
    BMC Cancer. 2025;25:951.
    >> Share

  315. SCHANTZ C, Gnangnon FHR, Aboubakar M, Agbodande AK, et al
    Barriers and opportunities related to access to oncology care in Benin: a qualitative study on breast cancer.
    BMC Cancer. 2025;25:947.
    >> Share

  316. NOPOUR R
    Prediction of one-year recurrence among breast cancer patients undergone surgery using artificial intelligence-based algorithms: a retrospective study on prognostic factors.
    BMC Cancer. 2025;25:940.
    >> Share

  317. HE C, Yu T, Yang L, He L, et al
    Clinical prediction of pathological complete response in breast cancer: a machine learning study.
    BMC Cancer. 2025;25:933.
    >> Share

  318. RAJABPOUR MV, Seyyedsalehi MS, Nahvijou A, Nemati S, et al
    Evaluating the breast cancer quality of care indicators in Iran; multicenter study.
    BMC Cancer. 2025;25:925.
    >> Share

  319. ARPINO G, De Angelis C, Gerratana L, Lambertini M, et al
    Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment study.
    BMC Cancer. 2025;25:920.
    >> Share

  320. NDLOVU AK, Kasvosve I, Rantshabeng PS, Sharma K, et al
    Female breast cancer classification using immunohistochemistry biomarkers staining in Botswana.
    BMC Cancer. 2025;25:893.
    >> Share

  321. LI H, Zhang CT, Shao HG, Pan L, et al
    Prediction models of breast cancer molecular subtypes based on multimodal ultrasound and clinical features.
    BMC Cancer. 2025;25:886.
    >> Share

  322. MOVAHED F, Dehbozorgi M, Goodarzi S, Abianeh FE, et al
    Effect of breast cancer surgery on levels of depression and anxiety: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:889.
    >> Share

  323. LU Y, Shi Z, Zhao Q, Bi Z, et al
    Exploring the clinical value of regional nodal irradiation in sentinel lymph node positive breast cancer patients omitting axillary dissection.
    BMC Cancer. 2025;25:866.
    >> Share

  324. ZARGARANI N, Kavousi M, Aliasgari E
    A potential new strategy for BC treatment: NPs containing solanine and evaluation of its anticancer and antimetastatic properties.
    BMC Cancer. 2025;25:860.
    >> Share

  325. BROWN C, Kang HA, Johnsrud M, Terry J, et al
    Assessing equity of care across metastatic breast cancer treatment junctures: a multi-site retrospective cohort study.
    BMC Cancer. 2025;25:861.
    >> Share

  326. KANG Y, Han B, Kong Y, Liu S, et al
    Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis.
    BMC Cancer. 2025;25:843.
    >> Share

  327. DE SOUZA MAMEDE VF, Bernabe RAM, Santos TG, da Silva LL, et al
    Risk of sarcopenia in women with breast cancer: a comparative analysis of screening tools.
    BMC Cancer. 2025;25:839.
    >> Share

  328. AHMAD S, Zafar I, Shafiq S, Sehar L, et al
    Deep learning-based computational approach for predicting ncRNAs-disease associations in metaplastic breast cancer diagnosis.
    BMC Cancer. 2025;25:830.
    >> Share

  329. YANG Y, Liao T, Lin XH, Ouyang R, et al
    Dual-region MRI radiomic analysis indicates increased risk in high-risk breast lesions: bridging intratumoral and peritumoral radiomics for precision decision-making.
    BMC Cancer. 2025;25:828.
    >> Share

  330. YILDIRIM S, Basoglu T, Dogan A, Akdag G, et al
    The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis.
    BMC Cancer. 2025;25:833.
    >> Share

    April 2025
  331. KHAN K, Anwar M, Badshah Y, Ashraf NM, et al
    Zapotin mitigates breast cancer progression by targeting PKCepsilon mediated glycolytic pathway regulation.
    BMC Cancer. 2025;25:798.
    >> Share

  332. HOLM JB, Bruun JM, Christiansen P, Thomsen RW, et al
    HbA(1c) levels and breast cancer prognosis in women without diabetes.
    BMC Cancer. 2025;25:790.
    >> Share

  333. ZHANG L, Li S, Shi J, Guo H, et al
    The LncRNA RMST-miR-4295-ITPR1 axis: a key mechanism in regulating autophagy in triple-negative breast cancer cells.
    BMC Cancer. 2025;25:782.
    >> Share

  334. LI Z, Zhao Z, Zhang T, Yang X, et al
    Association between triglyceride-glucose related indicators, genetic risk, and incident breast cancer among postmenopausal women in UK Biobank.
    BMC Cancer. 2025;25:781.
    >> Share

  335. ESMAELI M, Dehabadi MD, Khaleghi AA
    Cannabidiol as a novel therapeutic agent in breast cancer: evidence from literature.
    BMC Cancer. 2025;25:772.
    >> Share

  336. RAVEENDRAN C, Meloot SS, Yadev IP
    Clinical and biochemical amenorrhea in premenopausal patients with breast cancer treated with chemotherapy - a prospective cohort study.
    BMC Cancer. 2025;25:753.
    >> Share

  337. GLORY A, Patocskai E, Wong P
    Breast cancer PAINT: a first-in-human, dose-escalation study to determine the safety of Plasma Adjuvant INtra-operative Treatment in breast cancer patients.
    BMC Cancer. 2025;25:748.
    >> Share

  338. ZHANG Y, Wang H, Wang Y, Ma B, et al
    FOXO1 mediates miR-99a-5p/E2F7 to restrain breast cancer cell proliferation and induce apoptosis.
    BMC Cancer. 2025;25:747.
    >> Share

  339. GUPTA H, Raghubansi A, Bharat, Sharma K, et al
    Targeting GSK3beta and signaling pathways in breast cancer: role of individual members of miR- 23/24/27 cluster.
    BMC Cancer. 2025;25:737.
    >> Share

  340. CASTELLANO I, Rousset S, Casella D, Capella G, et al
    Early detection of triple-negative breast cancer: evidence of a favourable prognostic impact in a comparative analysis of screen-detected versus symptomatic cases.
    BMC Cancer. 2025;25:730.
    >> Share

  341. LIAN W, Li L, Chen D, Hong C, et al
    Adjuvant ovarian function suppression in premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a multi-center retrospective study.
    BMC Cancer. 2025;25:723.
    >> Share

  342. LIU J, Guan X, Gao S, Quan L, et al
    Novel insight of critical genes involved in breast cancer brain metastasis: evidence from a cross-tissue transcriptome association study and validation through external clinical cohorts.
    BMC Cancer. 2025;25:707.
    >> Share

  343. RASHID FA, Anwar W, Kandakurti PK, Al Qawasmeh KHA, et al
    Physical rehabilitation program for cardiorespiratory health and quality of life among breast cancer survivors in UAE: a randomized control trial.
    BMC Cancer. 2025;25:705.
    >> Share

  344. SAGDIC MF, Dincer B, Ozaslan C
    De-escalation of axillary surgery in early breast cancer: translating ACOSOG Z0011 study into clinical practice for breast-conserving surgery patients with positive sentinel lymph node biopsy.
    BMC Cancer. 2025;25:706.
    >> Share

  345. TANG H, Zhang W, Li X, Zou Q, et al
    Impact of early multidisciplinary team interventions on dietary management behavior in breast cancer patients: a pilot randomized controlled trial.
    BMC Cancer. 2025;25:699.
    >> Share

  346. LI Z, Miao H, Bao W, Zhang L, et al
    Development and validation of a nomogram model of lung metastasis in breast cancer based on machine learning algorithm and cytokines.
    BMC Cancer. 2025;25:692.
    >> Share

  347. LIN X, Yang H, Cai T, Yang Z, et al
    Polygonum multiflorum Stilbene Glycoside Oligomers induce the ferroptosis of triple negative breast cancer cells.
    BMC Cancer. 2025;25:676.
    >> Share

  348. ROUX A, Hervouet L, Di Stefano F, French DP, et al
    Correction: Acceptability of risk-based breast cancer screening among professionals and healthcare providers from 6 countries contributing to the MyPeBS study.
    BMC Cancer. 2025;25:687.
    >> Share

  349. GETU MA, Kaba M, Addissie A, Seife E, et al
    Patients' experiences of cognitive behavioural therapy integrated with activity pacing: a qualitative study.
    BMC Cancer. 2025;25:670.
    >> Share

  350. REN W, Yu Y, Wang T, Wang X, et al
    Comprehensive analysis of metabolism-related gene biomarkers reveals their impact on the diagnosis and prognosis of triple-negative breast cancer.
    BMC Cancer. 2025;25:668.
    >> Share

  351. BOSSON-AMEDENU S, Ayitey E, Ayiah-Mensah F, Asare L, et al
    Evaluating key predictors of breast cancer through survival: a comparison of AFT frailty models with LASSO, ridge, and elastic net regularization.
    BMC Cancer. 2025;25:665.
    >> Share

  352. ZHU W, Fang J, Zhang Y, Chen M, et al
    Validation of in vivo dose using EPID combined with fan-beam CT guidance in post-breast-conserving radiotherapy for early-stage breast cancer.
    BMC Cancer. 2025;25:667.
    >> Share

  353. AKHLAQI M, Ghofrani A, Najdi N, Ranjkesh M, et al
    A systematic review and meta-analysis of pregnancy-associated breast cancer incidence rate.
    BMC Cancer. 2025;25:660.
    >> Share

  354. TARAPARA B, Shah F
    Role of MRE11 in DNA damage repair pathway dynamics and its diagnostic and prognostic significance in hereditary breast and ovarian cancer.
    BMC Cancer. 2025;25:650.
    >> Share

  355. WANG S, Guo J, Xian X, Li M, et al
    Correction: Distinct 5-methylcytosine profiles of LncRNA in breast cancer brain metastasis.
    BMC Cancer. 2025;25:625.
    >> Share

  356. WANG G, Wang S, Song W, Lu C, et al
    Integrating multi-omics data reveals the antitumor role and clinical benefits of gamma-delta T cells in triple-negative breast cancer.
    BMC Cancer. 2025;25:623.
    >> Share

  357. ANDO Y, Miyadera H, Bando H, Hashimoto S, et al
    HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer.
    BMC Cancer. 2025;25:610.
    >> Share

  358. CARVALHO MM, Bah A, Azrib S, Hiatt RA, et al
    Evaluation of performance indicators of a national breast cancer screening program in Casablanca, Morocco.
    BMC Cancer. 2025;25:612.
    >> Share

  359. WU Z, Zhang R, Wu X, Meng X, et al
    Causal association of breast cancer with immune cells: new evidence from bi-directional Mendelian randomization using GWAS summary statistics.
    BMC Cancer. 2025;25:609.
    >> Share

  360. NIU R, Wang C, Xie Y, Li S, et al
    Prognostic significance of CD8 + tumor-infiltrating lymphocytes in operable breast cancer: a meta-analysis.
    BMC Cancer. 2025;25:601.
    >> Share

  361. SUN Y, Liao Q, Fan Y, Cui C, et al
    DCE-MRI radiomics of primary breast lesions combined with ipsilateral axillary lymph nodes for predicting efficacy of NAT.
    BMC Cancer. 2025;25:589.
    >> Share

    March 2025
  362. AN T, Han H, Xie J, Wang Y, et al
    Enhancing prediction and stratifying risk: machine learning and bayesian-learning models for catheter-related thrombosis in chemotherapy patients.
    BMC Cancer. 2025;25:552.
    >> Share

  363. WANG S, Guo J, Xian X, Li M, et al
    Distinct 5-methylcytosine profiles of LncRNA in breast cancer brain metastasis.
    BMC Cancer. 2025;25:557.
    >> Share

  364. HANNEMANN J, Oliveira-Ferrer L, Goele AK, Mileva Y, et al
    L-arginine dependence of breast cancer - molecular subtypes matter.
    BMC Cancer. 2025;25:546.
    >> Share

  365. CHERAGHALIZADEH H, Adib-Rad H, Pasha H, Chehrazi M, et al
    Effectiveness of face to face and virtual education to promote breast self-examination based on the theory of planned behavior: a randomized controlled trial study.
    BMC Cancer. 2025;25:548.
    >> Share

  366. TIAN H, Cai L, Gui Y, Cai Z, et al
    Two-stage augmentation for detecting malignancy of BI-RADS 3 lesions in early breast cancer.
    BMC Cancer. 2025;25:537.
    >> Share

  367. YEAN AW, Leong E, King OS, Mohamad Z, et al
    Breast cancer treatment modalities, treatment delays, and survival in Brunei Darussalam.
    BMC Cancer. 2025;25:510.
    >> Share

  368. MARBACH D, Brouer-Visser J, Brennan L, Wilson S, et al
    Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor).
    BMC Cancer. 2025;25:500.
    >> Share

  369. BERTOZZI S, Londero AP, Diaz Nanez JA, Di Vora R, et al
    Breast cancer care for the aging population: a focus on age-related disparities in breast cancer treatment.
    BMC Cancer. 2025;25:492.
    >> Share

  370. ROUX A, Hervouet L, Stefano FD, French DP, et al
    Acceptability of risk-based breast cancer screening among professionals and healthcare providers from 6 countries contributing to the MyPeBS study.
    BMC Cancer. 2025;25:483.
    >> Share

  371. ZHANG N, Shao X, Xu L, Zhu W, et al
    Three-dimensional turbo-spin-echo amide proton transfer-weighted and intravoxel incoherent motion imaging mri for triple-negative breast cancer: a comparison with molecular subtypes and histological grades.
    BMC Cancer. 2025;25:465.
    >> Share

  372. QIAN L, Cairong Z, Yongdong L, Quan L, et al
    Prognostic role of STMN1 expression and neoadjuvant therapy efficacy in breast cancer.
    BMC Cancer. 2025;25:453.
    >> Share

  373. TERREL-POCCOMO MK, Santillan-Romero G, Quispe-Vicuna C, Ybaseta-Medina J, et al
    Trends in breast cancer mortality in Peru and its geographical areas from 2013 to 2022 and prediction until 2027.
    BMC Cancer. 2025;25:463.
    >> Share

  374. BOUZID RS, Bouzid R, Labed H, Serhani I, et al
    Molecular subtyping and target identification in triple negative breast cancer through immunohistochemistry biomarkers.
    BMC Cancer. 2025;25:454.
    >> Share

  375. YARMAND S, Atashi N, Kazemi I, Mahmoudi-Zadeh M, et al
    Correction: Association of portfolio diet score with breast cancer risk: insights from a case-control analysis.
    BMC Cancer. 2025;25:448.
    >> Share

  376. RAVINDRANATH KJ, Srinivasan H
    Deciphering the anti-neoplastic potential of Allium ascalonicum in averting the proliferation and epithelial-mesenchymal transition of triple-negative breast cancer through virtual docking and In Vitro approaches.
    BMC Cancer. 2025;25:414.
    >> Share

  377. LIU X, Meng Q, Fan W, Ning L, et al
    The effects of intermittent fasting on anthropometric indices, glycemic profile, chemotherapy-related toxicity, and subjective perception in gynecological and breast cancer patients: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:419.
    >> Share

  378. XUE C, Yang W, Hu A, He C, et al
    CYP2D6 polymorphisms and endoxifen concentration in Chinese patients with breast cancer.
    BMC Cancer. 2025;25:410.
    >> Share

  379. MASELLI-SCHOUERI JH, De Carvalho LEW, De Melo Sette CV, de Abreu LC, et al
    How are we allocating physicians to deal with breast cancer in men and women in Brazil?
    BMC Cancer. 2025;25:392.
    >> Share

  380. KANWAL W, Narjis K, Musani S, Nancy F, et al
    Exploring Zanidatamab's efficacy across HER2-positive Malignancies: a narrative review.
    BMC Cancer. 2025;25:382.
    >> Share

    February 2025
  381. ZHANG K, Shen J, Liang Y, Meng X, et al
    Reduction of subclinical acute cardiac injury through DIBH radiotherapy: a single-institution real-world clinical cohort analysis.
    BMC Cancer. 2025;25:373.
    >> Share

  382. EGELBERG M, De Marchi T, Schultz N, Tran L, et al
    The potential radiosensitization target PFKFB3 is related to response to radiotherapy in SweBCG91RT: a randomized clinical trial with long-term follow-up.
    BMC Cancer. 2025;25:374.
    >> Share

  383. YAN M, Zong Z, Guo W, Li X, et al
    PIK3CA gene mutation status associated with poor prognosis of breast cancer: a retrospective cohort study.
    BMC Cancer. 2025;25:365.
    >> Share

  384. HAYES BL, Fleming L, Mahmoud O, Martin RM, et al
    The impact of sleep on breast cancer-specific mortality: a Mendelian randomisation study.
    BMC Cancer. 2025;25:357.
    >> Share

  385. WONGMANEERUNG P, Chitapanarux I, Traisathit P, Prasitwattanaseree S, et al
    The association between Ki-67 expression and survival in breast cancer subtypes: a cross-sectional study of Ki-67 cut-point in northern Thailand.
    BMC Cancer. 2025;25:346.
    >> Share

  386. LI Y, Song W, Gao P, Guan X, et al
    Global, regional, and national burden of breast, cervical, uterine, and ovarian cancer and their risk factors among women from 1990 to 2021, and projections to 2050: findings from the global burden of disease study 2021.
    BMC Cancer. 2025;25:330.
    >> Share

  387. RANTALA J, Seppa K, Eriksson J, Heinavaara S, et al
    Incidence trends of early-onset breast cancer by lifestyle risk factors.
    BMC Cancer. 2025;25:326.
    >> Share

  388. XIE L, Kong X, Lin D, Song J, et al
    Application of chest wall perforator flaps in oncoplastic breast-conserving surgery.
    BMC Cancer. 2025;25:328.
    >> Share

  389. HATLETVEDT ND, Engebrethsen C, Geisler J, Geisler S, et al
    The impact of functional MDM2-polymorphisms on neutrophil counts in breast cancer patients during neoadjuvant chemotherapy.
    BMC Cancer. 2025;25:308.
    >> Share

  390. WENWEN, Jiang Z, Liu J, Liu D, et al
    Integrating ultrasound radiomics and clinicopathological features for machine learning-based survival prediction in patients with nonmetastatic triple-negative breast cancer.
    BMC Cancer. 2025;25:291.
    >> Share

  391. WU X, Yuan F, Guo L, Gao D, et al
    Intraductal chemotherapy for triple-negative breast cancer: a pathway to minimally invasive clinical treatment.
    BMC Cancer. 2025;25:285.
    >> Share

  392. YARMAND S, Atashi N, Kazemi I, Mahmoudi-Zadeh M, et al
    Association of portfolio diet score with breast cancer risk: insights from a case-control analysis.
    BMC Cancer. 2025;25:274.
    >> Share

  393. ZENG Q, Deng Y, Nan J, Zou Z, et al
    Delta dual?region DCE-MRI radiomics from breast masses predicts axillary lymph node response after neoadjuvant therapy for breast cancer.
    BMC Cancer. 2025;25:264.
    >> Share

  394. XIE H, Tan T, Li Q, Li T, et al
    Revolutionizing HER-2 assessment: multidimensional radiomics in breast cancer diagnosis.
    BMC Cancer. 2025;25:265.
    >> Share

  395. ZANGOURI V, Balaneji SS, Golmoradi R, Kafili E, et al
    Effects of BMI on prognosis, disease-free survival and overall survival of breast cancer.
    BMC Cancer. 2025;25:257.
    >> Share

  396. FAMILI-YOUTH EHH, Famili-Youth A, Yang D, Siddique A, et al
    Aberrant expression of collagen type X in solid tumor stroma is associated with EMT, immunosuppressive and pro-metastatic pathways, bone marrow stromal cell signatures, and poor survival prognosis.
    BMC Cancer. 2025;25:247.
    >> Share

  397. ZHANG J, Wang Y, Liu Y, Chen H, et al
    Proteomic profiling reveals biological processes and biomarkers involved in the pathogenesis of occult breast cancer.
    BMC Cancer. 2025;25:231.
    >> Share

  398. JIAO D, Chen X, Sun X, Lu Z, et al
    A comparative study of mitoxantrone hydrochloride injection and technetium-99 m for tracing axillary sentinel nodes in patients with breast cancer.
    BMC Cancer. 2025;25:209.
    >> Share

  399. YAMADA M, Chishima T, Ishikawa T, Narui K, et al
    Breast cancer risk assessment based on a predictive model: evaluation of risk factors among Japanese women.
    BMC Cancer. 2025;25:206.
    >> Share

  400. SHEIKHNEZHAD L, Hassankhani H, Sawin EM, Sanaat Z, et al
    What does intimate partner violence mean for women with breast cancer? Experiences of Iranian women.
    BMC Cancer. 2025;25:190.
    >> Share

    January 2025
  401. GETIE M, Mekonnen BA, Seifu D, Mulugeta Y, et al
    Serum cardiac and inflammatory biomarker levels following chemotherapy among female patients with breast cancer attending at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.
    BMC Cancer. 2025;25:175.
    >> Share

  402. GODIVEAU M, Passildas J, Thivat E, Casile M, et al
    Post-therapeutic support and rehabilitation for breast cancer women in complete remission in a thermal resort: study protocol for the PACThe Real-Life conditions observational trial.
    BMC Cancer. 2025;25:174.
    >> Share

  403. KAUTZ-FREIMUTH S, Shukri A, Stracke C, Isselhard A, et al
    Factors influencing role preferences in decision-making of healthy women with BRCA1/2 pathogenic variants: subanalysis from a randomised controlled decision coaching trial.
    BMC Cancer. 2025;25:164.
    >> Share

  404. WANG Y, Wang R, Lu D, Zeng Y, et al
    Predictive factors for axillary pathological complete response to neoadjuvant therapy in elderly breast cancer patients.
    BMC Cancer. 2025;25:156.
    >> Share

  405. BHANGDIA K, Natarajan A, Rudolfson N, Verguet S, et al
    The association of travel distance and other patient characteristics with breast cancer stage at diagnosis and treatment completion at a rural Rwandan cancer facility.
    BMC Cancer. 2025;25:146.
    >> Share

  406. PETE R, Pinard C, Sirodot F, Molnar I, et al
    Patient satisfaction with radio-frequency identification (RFID) tag localization compared with wire localization for nonpalpable breast lesions: the RFID trial.
    BMC Cancer. 2025;25:123.
    >> Share

  407. JEONG SH, Chun SM, Kim M, Lee YS, et al
    Multimodal treatments and the risk of breast cancer-related lymphedema: insights from a nationally representative cohort in South Korea.
    BMC Cancer. 2025;25:114.
    >> Share

  408. NIU S, Sun T, Wang M, Yao L, et al
    Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis.
    BMC Cancer. 2025;25:115.
    >> Share

  409. BRANDSTETTER LS, Grau A, Heuschmann PU, Muller-Reiter M, et al
    Medication patterns and potentially inappropriate medication in patients with metastatic breast cancer: results of the BRE-BY-MED study.
    BMC Cancer. 2025;25:125.
    >> Share

  410. SAFIEDDINE B, Geyer S, Sperlich S, Beller J, et al
    Factors associated with health-related quality of life in women with paid work at breast cancer diagnosis: a German repeated cross-sectional study over the first five years after primary surgery.
    BMC Cancer. 2025;25:98.
    >> Share

  411. BECK MH, Brachaczek IA, Gebert P, Blohmer JU, et al
    Incidence of seroma and postoperative complications after breast surgery before and during the Covid-19 pandemic: results from a retrospective multicenter analysis.
    BMC Cancer. 2025;25:91.
    >> Share

  412. LIU M, Kilbreath S, Yee J, Beith J, et al
    Motivations and perceptions for physical activity in women living with metastatic breast cancer: a qualitative interview study.
    BMC Cancer. 2025;25:80.
    >> Share

  413. BOVELL AAN, Ramaliba T, Goodwin SO, Phillip JC, et al
    Incidence, trends and patterns of female breast, cervical, colorectal and prostate cancers in Antigua and Barbuda, 2017-2021: a retrospective study.
    BMC Cancer. 2025;25:72.
    >> Share

  414. CUMMINGS-JOHN C, Bah AJ, Smalle IO, Challe CC, et al
    The patterns of presentation, management and outcomes of breast cancer patients at a tertiary health facility in Sierra Leone.
    BMC Cancer. 2025;25:70.
    >> Share

  415. FENG Y, Song Q, Yan L, Li R, et al
    Predicting breast cancer prognosis using PR and PIK3CA biomarkers: a comparative analysis of diagnostic groups.
    BMC Cancer. 2025;25:68.
    >> Share

  416. ZHANG F, Wang S, Liu B, Yang W, et al
    Role of immediate injection of methylene blue after fiberoptic ductoscopy in selective ductectomy for patients with pathological nipple discharge.
    BMC Cancer. 2025;25:60.
    >> Share

  417. LIU M, Kilbreath S, Yee J, Beith J, et al
    Personal and behavioural factors that influence physical activity in women living with metastatic breast cancer: a qualitative interview study.
    BMC Cancer. 2025;25:48.
    >> Share

  418. CHE J, Chen B, Wang X, Liu B, et al
    Correlation analysis of DLG5 and PD-L1 expression in triple-negative breast cancer.
    BMC Cancer. 2025;25:35.
    >> Share

  419. XU L, Li P, Hu Y, Xing W, et al
    Cross-cultural adaptation of the simple Chinese version of the medication adherence reasons scale in patients undergoing adjuvant endocrine therapy for breast cancer.
    BMC Cancer. 2025;25:41.
    >> Share

  420. WANG Z, Bi Z, Bo H, Xu J, et al
    PRAF2 as a novel biomarker for breast cancer with machine learning and experimentation validation.
    BMC Cancer. 2025;25:32.
    >> Share

  421. TANG J, Guo B, Zhong C, Chi J, et al
    Detection of differences in physical symptoms between depressed and undepressed patients with breast cancer: a study using K-medoids clustering.
    BMC Cancer. 2025;25:23.
    >> Share

  422. VAYNRUB A, Salazar B, Feng YE, West H, et al
    The breast cancer genetic testing experience: probing the potential utility of an online decision aid in risk perception and decision making.
    BMC Cancer. 2025;25:19.
    >> Share

  423. DA SILVA JL, Thuler LCS, de Melo AC
    Breast cancer patterns by age groups in Brazil: insights from population-based registries data.
    BMC Cancer. 2025;25:18.
    >> Share

  424. NTEKIM A, Folasire A, Odukoya OA, Sowunmi A, et al
    Pathway to care among adolescents and young adults with breast cancer in Nigeria: a mixed methods study.
    BMC Cancer. 2025;25:11.
    >> Share

  425. LONG Z, Qiu Y, Long Z, Jin Z, et al
    Epidemiology of breast cancer in Chinese women from 1990 to 2021: a systematic analysis and comparison with the global burden.
    BMC Cancer. 2025;25:3.
    >> Share

  426. LIU J, Zhang J, Li H, Song G, et al
    Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study.
    BMC Cancer. 2025;25:9.
    >> Share

    December 2024
  427. GLYNOU SP, Sousi S, Cook H, Zargaran A, et al
    A comparison of acellular dermal matrices (ADM) efficacy and complication profile in women undergoing implant-based breast reconstruction: a systematic review and network meta-analysis.
    BMC Cancer. 2024;24:1598.
    >> Share

  428. KAHRAMAN S, Hizal M, Demirel BC, Guven DC, et al
    Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study.
    BMC Cancer. 2024;24:1592.
    >> Share

  429. LEE J, Kang B, Jung JH, Kim HJ, et al
    Feasibility of an indocyanine green-hyaluronic acid mixture (LuminoMark) for targeting suspicious axillary lymph nodes in patients with breast cancer.
    BMC Cancer. 2024;24:1588.
    >> Share

  430. ZHANG F, Wang S, Yu C, Jin W, et al
    The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy.
    BMC Cancer. 2024;24:1585.
    >> Share

  431. LIU J, Sun Y, Qi P, Wo Y, et al
    Gene expression profiling for the diagnosis of male breast cancer.
    BMC Cancer. 2024;24:1584.
    >> Share

  432. CHEN Y, He J, Song T, Zhang Y, et al
    Comparing supraclavicular surgery with radiotherapy versus radiotherapy alone in breast cancer patients with ipsilateral supraclavicular lymph node metastasis: a two-center retrospective cohort study.
    BMC Cancer. 2024;24:1572.
    >> Share

  433. KIRLI BOLUKBAS M, Figen M, Kocak Uzel E
    Cancer awareness across borders: a comparative study of internet search trends for breast and prostate cancer in Europe and Turkey.
    BMC Cancer. 2024;24:1563.
    >> Share

  434. SUN H, Liang J, Xue S, Zhang X, et al
    Establishment and clinical application of a prognostic index for inflammatory status in triple-negative breast cancer patients undergoing neoadjuvant therapy using machine learning.
    BMC Cancer. 2024;24:1559.
    >> Share

  435. SCHMIDT M, Vernooij R, van Nuland M, Smeijsters E, et al
    Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival.
    BMC Cancer. 2024;24:1553.
    >> Share

  436. AZIZ M, Ejaz SA, Channar PA, Alkhathami AG, et al
    Identification of dimethyl 2,2'-((methylenebis(2-(2H-benzo[d][1,2,3]triazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)-6,1phenylene))bis(oxy))diacetate (TAJ4) as antagonist of NEK-Family: a future for potential drug discovery.
    BMC Cancer. 2024;24:1521.
    >> Share

  437. ZHANG X, Zhang Y, Du W
    Alleviating role of ketamine in breast cancer cell-induced osteoclastogenesis and tumor bone metastasis-induced bone cancer pain through an SRC/EGR1/CST6 axis.
    BMC Cancer. 2024;24:1535.
    >> Share

  438. GNANGNON FHR, Lawani I, Knight SR, Parente A, et al
    Assessing the continuum of care in Sub-Saharan African hospitals performing surgery for breast cancer: a secondary analysis of the GlobalSurg 3 study.
    BMC Cancer. 2024;24:1529.
    >> Share

  439. WANG Y, Zhong P, Wang C, Huang W, et al
    Genetic overlap between breast cancer and sarcopenia: exploring the prognostic implications of SLC38A1 gene expression.
    BMC Cancer. 2024;24:1533.
    >> Share

  440. EKHOLM A, Wang Y, Vallon-Christersson J, Boissin C, et al
    Prediction of gene expression-based breast cancer proliferation scores from histopathology whole slide images using deep learning.
    BMC Cancer. 2024;24:1510.
    >> Share

  441. NOMAN S, Elarusy NME, Rahman HA, Ismail S, et al
    Investigating the effect of the educational intervention based on the Health Belief Model on the knowledge and beliefs of Yemeni teachers in the use of breast cancer screening: a randomized controlled trial study.
    BMC Cancer. 2024;24:1506.
    >> Share

  442. BOAITEY GA, Martini R, Stonaker B, Bonsu EO, et al
    Patterns of breast cancer locoregional relapse, metastasis, and subtypes in Ghana.
    BMC Cancer. 2024;24:1485.
    >> Share

    November 2024
  443. RONG RY, Shen YK, Wu SN, Xu SH, et al
    Prediction model for ocular metastasis of breast cancer: machine learning model development and interpretation study.
    BMC Cancer. 2024;24:1472.
    >> Share

  444. LI Y, Yang X, Ma L
    Prognostic prediction for HER2-low breast cancer patients using a novel machine learning model.
    BMC Cancer. 2024;24:1474.
    >> Share

  445. KVERNROD AB, Rasmussen CH, Pedersen LH, Bojesen SE, et al
    Attitudes towards risk-stratified breast cancer screening in Denmark - a qualitative study.
    BMC Cancer. 2024;24:1453.
    >> Share

  446. ZHANG H, Jin J, Li L, Wang L, et al
    Outcome and toxicities of postmastectomy radiotherapy with integral cervicothoracic thermoplastic mask.
    BMC Cancer. 2024;24:1445.
    >> Share

  447. MO JL, Li X, Lei L, Peng J, et al
    A machine learning model revealed that exosome small RNAs may participate in the development of breast cancer through the chemokine signaling pathway.
    BMC Cancer. 2024;24:1435.
    >> Share

  448. MEHNERT E, Moller FS, Hofbauer C, Weidlich A, et al
    Palliative care of proximal femur metastatic disease and osteolytic lesions: results following surgical and radiation treatment.
    BMC Cancer. 2024;24:1431.
    >> Share

  449. QIAN C, Xing Y, Cheng W
    Causal effect between breast cancer and ovarian cancer: a two-sample mendelian randomization study.
    BMC Cancer. 2024;24:1433.
    >> Share

  450. MALMSTROM M, Holst-Hansson A, Olsson Moller U
    The complexity of needs and roles of family members during breast cancer rehabilitation: a qualitative study.
    BMC Cancer. 2024;24:1430.
    >> Share

  451. SHI S, Ma HY, Sang YZ, Ju YB, et al
    CD147 expression as a clinicopathological and prognostic indicator in breast cancer: a meta-analysis and bioinformatics analysis.
    BMC Cancer. 2024;24:1429.
    >> Share

  452. POWLA PP, Medina H, Villamar D, Huard C, et al
    Racial disparities in the frequency and timing of code status orders among women with breast cancer.
    BMC Cancer. 2024;24:1426.
    >> Share

  453. SCHUMACHER TJ, Iyer AV, Rumbley J, Ronayne CT, et al
    Exploring the impact of mitochondrial-targeting anthelmintic agents with GLUT1 inhibitor BAY-876 on breast cancer cell metabolism.
    BMC Cancer. 2024;24:1415.
    >> Share

  454. GOTINK J, Rosskamp M, Silversmit G, Verdoodt F, et al
    Exploring educational disparities in breast cancer dynamics: a comprehensive analysis of incidence, death within 5 years of diagnosis, and mortality in the Belgian context.
    BMC Cancer. 2024;24:1399.
    >> Share

  455. SRIVASTAVA TP, Ajmeriya S, Goel I, Talukdar J, et al
    Prognostic role of Androgen Receptor splice variant 7 (AR-V7) in the pathogenesis of breast cancer.
    BMC Cancer. 2024;24:1398.
    >> Share

  456. XU Y, Huang L, Wang J, He J, et al
    Exploring optimal administration timing of pegylated recombinant human granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in early breast cancer treated with pharmorubicin and endoxan: a prospective randomized controlled clinic
    BMC Cancer. 2024;24:1387.
    >> Share

  457. YOON SH, Lee S, Kim HS, Song J, et al
    NSDHL contributes to breast cancer stem-like cell maintenance and tumor-initiating capacity through TGF-beta/Smad signaling pathway in MCF-7 tumor spheroid.
    BMC Cancer. 2024;24:1370.
    >> Share

  458. BI Z, Cheng WH, Zheng WH, Ren TY, et al
    The optimal timing of breast cancer surgery after COVID-19 infection: an observational study.
    BMC Cancer. 2024;24:1348.
    >> Share

    October 2024
  459. WANG Z, You P, Yang Z, Xiao H, et al
    PD-1/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer: a meta-analysis on their efficacy and safety.
    BMC Cancer. 2024;24:1339.
    >> Share

  460. KATAOKA N, Hata T, Hosomi K, Hirata A, et al
    Predictors of abemaciclib discontinuation in patients with breast cancer: a multicenter retrospective cohort study.
    BMC Cancer. 2024;24:1335.
    >> Share

  461. ONER I, Turkel A, Inci BK, Tolunay PK, et al
    Impact of the CPS-EG score as a new prognostic biomarker in triple-negative breast cancer patients who received neoadjuvant chemotherapy.
    BMC Cancer. 2024;24:1338.
    >> Share

  462. GARCIA-HERNANDEZ AP, Corona DN, Carlos-Reyes A, Sierra-Martinez M, et al
    The lncRNA AFAP1-AS1 is upregulated in metastatic triple-negative breast tumors and controls hypoxia-activated vasculogenic mimicry and angiogenesis.
    BMC Cancer. 2024;24:1332.
    >> Share

  463. NEVIERE Z, Blanc-Fournier C, Guizard AV, Elie N, et al
    Potential of PSMA for breast cancer in nuclear medicine: digital quantitative immunohistochemical analysis and implications for a theranostic approach.
    BMC Cancer. 2024;24:1328.
    >> Share

  464. JIAO S, Wang Y, Ma J, Shen J, et al
    Interobserver variability of clinical target volume delineation in patients undergoing breast-conserving surgery without surgical clips: a pilot study on preoperative magnetic resonance simulation.
    BMC Cancer. 2024;24:1321.
    >> Share

  465. MSAMI K, Nyamle N, Ruwaichi T, Chuwa H, et al
    Strengthening uptake of breast cancer screening services in Tanzania; re-visiting the breast cancer screening messages.
    BMC Cancer. 2024;24:1312.
    >> Share

  466. YANG L, Ding H, Gao X, Xu Y, et al
    Can we skip invasive biopsy of sentinel lymph nodes? A preliminary investigation to predict sentinel lymph node status using PET/CT-based radiomics.
    BMC Cancer. 2024;24:1316.
    >> Share

  467. SANTOS TG, da Silva LL, Bernabe RAM, Albergaria BH, et al
    Anthropometric equation has sufficient diagnostic capacity to identify sarcopenia in women with breast cancer.
    BMC Cancer. 2024;24:1310.
    >> Share

  468. SEN GA, Aydin E, Guliyev M, Oztas NS, et al
    The impact of HER2-low status on pathological complete response and disease-free survival in early-stage breast cancer.
    BMC Cancer. 2024;24:1311.
    >> Share

  469. HACHACHE R, Yahyaouy A, Riffi J, Tairi H, et al
    Advancing personalized oncology: a systematic review on the integration of artificial intelligence in monitoring neoadjuvant treatment for breast cancer patients.
    BMC Cancer. 2024;24:1300.
    >> Share

  470. BATCHELOR S, Lunnay B, Macdonald S, Ward PR, et al
    How social class shapes breast cancer risk perspectives and prevention practices of Australian midlife women: a qualitative study using the concept of 'breast cancer candidacy'.
    BMC Cancer. 2024;24:1295.
    >> Share

  471. CUI M, Fu J, Li Q
    Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis.
    BMC Cancer. 2024;24:1293.
    >> Share

  472. LIU J, He M, Jiang M, Zhou S, et al
    Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study.
    BMC Cancer. 2024;24:1290.
    >> Share

  473. ZIEGLER P, Hartkopf AD, Wallwiener M, Haberle L, et al
    The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype.
    BMC Cancer. 2024;24:1284.
    >> Share

  474. CHEN W, Pang L, Jin X, Chen H, et al
    Targeted axillary dissection using carbon marking for patients with node-positive breast cancer following neoadjuvant therapy (TADCOM): study protocol for a prospective, multicenter, randomized controlled trial.
    BMC Cancer. 2024;24:1276.
    >> Share

  475. WANG L, Zhen M, Liao L, Li H, et al
    Effects of dietary habits and catheterization type on breast cancer-related lymphedema: a retrospective cohort study.
    BMC Cancer. 2024;24:1264.
    >> Share

  476. WANG Y, Xu H, Sa Q, Li L, et al
    Development of graded prognostic assessment for breast Cancer brain metastasis incorporating extracranial metastatic features: a retrospective analysis of 284 patients.
    BMC Cancer. 2024;24:1262.
    >> Share

  477. ZHAO Y, He M, Cui L, Zhang M, et al
    Systematic screening of protein-coding gene expression identified VWF as a potential key regulator in anthracycline-based chemotherapy-exacerbated metastasis of breast cancer.
    BMC Cancer. 2024;24:1243.
    >> Share

  478. LI Z, Jian C, Li Y, Pan Z, et al
    Clinical benefits of deep inspiration breath-hold in postoperative radiotherapy for right-sided breast cancer: a meta-analysis.
    BMC Cancer. 2024;24:1238.
    >> Share

  479. REN K, Wang S, Ye T, Zhu Z, et al
    Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC).
    BMC Cancer. 2024;24:1237.
    >> Share

  480. NOURI M, Mansouri F, Jafari F, Ranjbar Zahedani M, et al
    Association between processed and ultra-processed food intake and the risk of breast cancer: a case-control study.
    BMC Cancer. 2024;24:1234.
    >> Share

  481. DO TM, Nguyen QHN, Le NHD, Nguyen HD, et al
    Association between dietary factors and breast cancer risk: a matched case-control study in Vietnam.
    BMC Cancer. 2024;24:1224.
    >> Share

  482. MA H, Shi L, Zheng J, Zeng L, et al
    Advanced machine learning unveils CD8 + T cell genetic markers enhancing prognosis and immunotherapy efficacy in breast cancer.
    BMC Cancer. 2024;24:1222.
    >> Share

    September 2024
  483. BAHARUN NB, Adam A, Zailani MAH, Rajpoot NM, et al
    Automated scoring methods for quantitative interpretation of Tumour infiltrating lymphocytes (TILs) in breast cancer: a systematic review.
    BMC Cancer. 2024;24:1202.
    >> Share

  484. XIONG Z, Liu K, Liu S, Feng J, et al
    Precision HER2: a comprehensive AI system for accurate and consistent evaluation of HER2 expression in invasive breast Cancer.
    BMC Cancer. 2024;24:1204.
    >> Share

  485. WANG D, Xie D, Meng S, Mi J, et al
    Role and molecular mechanisms of HuangQiSiJunZi decoction for treating triple-negative breast cancer as explored via network pharmacology and bioinformatics analyses.
    BMC Cancer. 2024;24:1217.
    >> Share

  486. NI M, Zhou L, Lu Y, Guo D, et al
    Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study.
    BMC Cancer. 2024;24:1214.
    >> Share

  487. RAN R, Zhao S, Zhou Y, Hang X, et al
    Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study.
    BMC Cancer. 2024;24:1216.
    >> Share

  488. REZAIE-CHAMANI S, Lamyian M, Ahmadi F, Montazeri A, et al
    I trust doctors and midwives: exploring breast cancer literacy among women referring to the health centers in Iran.
    BMC Cancer. 2024;24:1201.
    >> Share

  489. OGUNMODEDE EO, Ajala DE, Aluko JO, Anokwuru RA, et al
    Promoting breast health among female adolescents: a comparative analysis of the effects of two didactic tools on knowledge and practice regarding breast self-examination in Southwest Nigeria.
    BMC Cancer. 2024;24:1183.
    >> Share

  490. COOK HI, Glynou SP, Sousi S, Zargaran D, et al
    Does the use of Acellular Dermal Matrices (ADM) in women undergoing pre-pectoral implant-based breast reconstruction increase operative success versus non-use of ADM in the same setting? A systematic review.
    BMC Cancer. 2024;24:1186.
    >> Share

  491. HU S, Tey SK, Kwong A
    Adipogenesis biomarkers as the independent predictive factors for breast cancer recurrence: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:1181.
    >> Share

  492. WU F, Li N, Wu X, Chen M, et al
    EZH2 mutation is associated with the development of visceral metastasis by enhancing proliferation and invasion and inhibiting apoptosis in breast cancer cells.
    BMC Cancer. 2024;24:1166.
    >> Share

  493. TANG M, Rong Y, Li X, Pan H, et al
    Anoikis-related genes in breast cancer patients: reliable biomarker of prognosis.
    BMC Cancer. 2024;24:1163.
    >> Share

  494. KOBAYASHI T, Nishimura M, Hosonaga M, Kizawa R, et al
    Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer.
    BMC Cancer. 2024;24:1156.
    >> Share

  495. CHENG Z, Xu H, Wang X, Teng T, et al
    A causal relationship between bone mineral density and breast cancer risk: a mendelian randomization study based on east Asian population.
    BMC Cancer. 2024;24:1148.
    >> Share

  496. ZHANG Q, Wang Z, Yao W, Wang S, et al
    A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.
    BMC Cancer. 2024;24:1143.
    >> Share

  497. CANCILLA MA, Nemati D, Halsey D, Shah N, et al
    Exercise as part of survivorship care in metastatic breast cancer: protocol for the randomized EMBody trial.
    BMC Cancer. 2024;24:1137.
    >> Share

  498. YU X, Yu Y, Huang X, Jiang Z, et al
    Unraveling the causal links and novel molecular classification of Crohn's disease in breast Cancer: a two-sample mendelian randomization and transcriptome analysis with prognostic modeling.
    BMC Cancer. 2024;24:1134.
    >> Share

  499. BALLE JK, Vetter M, Kenea TW, Eber-Schulz P, et al
    PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study.
    BMC Cancer. 2024;24:1127.
    >> Share

  500. DESWAL B, Bagchi U, Santra MK, Garg M, et al
    Inhibition of STAT3 by 2-Methoxyestradiol suppresses M2 polarization and protumoral functions of macrophages in breast cancer.
    BMC Cancer. 2024;24:1129.
    >> Share

  501. LI H, Xu Y, Xu R, Du W, et al
    The role of HGH1 in breast cancer prognosis: a study on immune response and cell cycle.
    BMC Cancer. 2024;24:1122.
    >> Share

  502. KELLEY-JONES C, Scott SE, Waller J
    Acceptability of de-intensified screening for women at low risk of breast cancer: a randomised online experimental survey.
    BMC Cancer. 2024;24:1111.
    >> Share

  503. FASSIER JB, Guittard L, Fervers B, Rouat S, et al
    Using intervention mapping to facilitate and sustain return-to work after breast cancer: protocol for the FASTRACS multicentre randomized controlled trial.
    BMC Cancer. 2024;24:1107.
    >> Share

  504. DANDENA FG, Teklewold BT, Darebo TD, Suga YD, et al
    Epidemiology and clinical characteristics of breast cancer in Ethiopia: a systematic review.
    BMC Cancer. 2024;24:1102.
    >> Share

  505. XIE X, Fang Y, He L, Chen Z, et al
    Individualized prediction of non-sentinel lymph node metastasis in Chinese breast cancer patients with >/= 3 positive sentinel lymph nodes based on machine-learning algorithms.
    BMC Cancer. 2024;24:1090.
    >> Share

    August 2024
  506. LIN TE, Wong AW, Cheong DC, Kuo WL, et al
    Strategically shifting paradigms: the new era of DIEP flaps with minimally invasive mastectomy: a retrospective cross-sectional study.
    BMC Cancer. 2024;24:1072.
    >> Share

  507. SONG MY, Zhao L, Huang WJ, Cui MM, et al
    Preoperative platelet distribution width predicts bone metastasis in patients with breast cancer.
    BMC Cancer. 2024;24:1066.
    >> Share

  508. TANG W, Gao Y, Hong S, Wang S, et al
    GFPT1 accelerates immune escape in breast cancer by modifying PD-L1 via O-glycosylation.
    BMC Cancer. 2024;24:1071.
    >> Share

  509. WANG L, Hong R, Shi S, Wang S, et al
    The prognostic significance of circulating tumor cell enumeration and HER2 expression by a novel automated microfluidic system in metastatic breast cancer.
    BMC Cancer. 2024;24:1067.
    >> Share

  510. GAO X, Pan T, Gao Y, Zhu W, et al
    Acetylation of PGK1 at lysine 323 promotes glycolysis, cell proliferation, and metastasis in luminal A breast cancer cells.
    BMC Cancer. 2024;24:1054.
    >> Share

  511. ZHANG J, Sun H, Gao S, Kang Y, et al
    Prediction of disease-free survival using strain elastography and diffuse optical tomography in patients with T1 breast cancer: a 10-year follow-up study.
    BMC Cancer. 2024;24:1057.
    >> Share

  512. LUO C, Yu K, Luo X, Lian T, et al
    CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis.
    BMC Cancer. 2024;24:1031.
    >> Share

  513. CHEN JH, Addanki S, Roy D, Bassett R, et al
    Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA.
    BMC Cancer. 2024;24:1016.
    >> Share

  514. BEKELE K, Nugusu F, Beressa G, Hollis T, et al
    Proportion of early-stage breast cancer at diagnosis in Ethiopia: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:1017.
    >> Share

  515. DAJSAKDIPON T, Susiriwatananont T, Wongkraisri C, Ithimakin S, et al
    Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand.
    BMC Cancer. 2024;24:1018.
    >> Share

  516. HU L, Gu Y, Xu W, Wang C, et al
    Association of clinicopathologic and sonographic features with stromal tumor-infiltrating lymphocytes in triple-negative breast cancer.
    BMC Cancer. 2024;24:997.
    >> Share

  517. AHMADIRAD H, Norouzzadeh M, Teymoori F, Jahromi MK, et al
    The predictive role of the total potassium intake and odds of breast cancer: a case-control study.
    BMC Cancer. 2024;24:995.
    >> Share

  518. KAWAMOTO Y, Yamai T, Ikezawa K, Seiki Y, et al
    Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer.
    BMC Cancer. 2024;24:1000.
    >> Share

  519. ELZOHERY YHAM, Radwan AH, Gareer SWY, Mamdouh MM, et al
    Micropapillary breast carcinoma in comparison with invasive duct carcinoma. Does it have an aggressive clinical presentation and an unfavorable prognosis?
    BMC Cancer. 2024;24:992.
    >> Share

  520. LI K, Chai D, Ren S, Lian X, et al
    beta2-microglobulin induced apoptosis of tumor cells via the ERK signaling pathway by directly interacting with HFE in HER2-overexpressing breast cancer.
    BMC Cancer. 2024;24:991.
    >> Share

  521. LIN W, Gu C, Chen Z, Xue S, et al
    Exploring the relationship between gut microbiota and breast cancer risk in European and East Asian populations using Mendelian randomization.
    BMC Cancer. 2024;24:970.
    >> Share

  522. WOJCIK KM, Caswell-Jin JL, Wilson OWA, Schechter C, et al
    The population-level effects of omitting chemotherapy guided by a 21-gene expression assay in node-positive breast cancer: a simulation modeling study.
    BMC Cancer. 2024;24:975.
    >> Share

  523. HEMATI M, Rivaz M, Khademian Z
    Lymphedema self-management mobile application with nurse support for post breast cancer surgery survivors: description of the design process and prototype evaluation.
    BMC Cancer. 2024;24:973.
    >> Share

  524. LEE TF, Chang CH, Chi CH, Liu YH, et al
    Utilizing radiomics and dosiomics with AI for precision prediction of radiation dermatitis in breast cancer patients.
    BMC Cancer. 2024;24:965.
    >> Share

    July 2024
  525. WAN LW, Zhang C, Zhang YL, Lin F, et al
    Prognostic significance of the novel immunonutritional marker of cholesterol-to-lymphocyte ratio in patients with non-metastatic breast cancer.
    BMC Cancer. 2024;24:914.
    >> Share

  526. HU ZY, Liu B, Xie N, Yang X, et al
    The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study.
    BMC Cancer. 2024;24:915.
    >> Share

  527. ANABA EA, Alor SK, Badzi CD, Mbuwir CB, et al
    Drivers of breast cancer and cervical cancer screening among women of reproductive age: insights from the Ghana Demographic and Health Survey.
    BMC Cancer. 2024;24:920.
    >> Share

  528. WANG X, Nie L, Zhu Q, Zuo Z, et al
    Artificial intelligence assisted ultrasound for the non-invasive prediction of axillary lymph node metastasis in breast cancer.
    BMC Cancer. 2024;24:910.
    >> Share

  529. RAEI M, Heydari K, Tabarestani M, Razavi A, et al
    Diagnostic accuracy of ESR1 mutation detection by cell-free DNA in breast cancer: a systematic review and meta-analysis of diagnostic test accuracy.
    BMC Cancer. 2024;24:908.
    >> Share

  530. LI X, Cheng K, Shang MD, Yang Y, et al
    MARCH1 negatively regulates TBK1-mTOR signaling pathway by ubiquitinating TBK1.
    BMC Cancer. 2024;24:902.
    >> Share

  531. YIALLOUROU A, Pantavou K, Markozannes G, Pilavas A, et al
    Non-genetic factors and breast cancer: an umbrella review of meta-analyses.
    BMC Cancer. 2024;24:903.
    >> Share

  532. JIANG M, Chai Y, Liu J, He M, et al
    Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis.
    BMC Cancer. 2024;24:877.
    >> Share

  533. TANG H, Zhang W, Shen H, Tang H, et al
    A protocol for a multidisciplinary early intervention during chemotherapy to improve dietary management behavior in breast cancer patients: a two-arm, single-center randomized controlled trial.
    BMC Cancer. 2024;24:859.
    >> Share

  534. SOHRABEI S, Moghaddasi H, Hosseini A, Ehsanzadeh SJ, et al
    Investigating the effects of artificial intelligence on the personalization of breast cancer management: a systematic study.
    BMC Cancer. 2024;24:852.
    >> Share

  535. CHRISTINE D, Christian SF, Ricarda K, Christine K, et al
    Risk factors for residual fibroglandular breast tissue following a mastectomy - an overview and retrospective cohort study.
    BMC Cancer. 2024;24:856.
    >> Share

  536. JIA L, Peng J, Sun N, Chen H, et al
    Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy.
    BMC Cancer. 2024;24:850.
    >> Share

  537. DAMTIE Z, Cherie N, Agidew MM
    Breast cancer preventive practices and associated factors among reproductive age women in Wadila District, North East Ethiopia: community based cross-sectional study.
    BMC Cancer. 2024;24:843.
    >> Share

  538. POMEY MP, Iliescu Nelea M, Vialaron C, Normandin L, et al
    The black box of the relationship between breast cancer patients and accompanying patients: the accompanied patients' point of view.
    BMC Cancer. 2024;24:822.
    >> Share

  539. PIAO YJ, Kim HS, Kim H, Shen J, et al
    SerpinB2 deficiency is associated with delayed mammary tumor development and decreased pro-tumorigenic macrophage polarization.
    BMC Cancer. 2024;24:792.
    >> Share

  540. PENG J, Lin Y, Sheng X, Yuan C, et al
    Serum miRNA-1 may serve as a promising noninvasive biomarker for predicting treatment response in breast cancer patients receiving neoadjuvant chemotherapy.
    BMC Cancer. 2024;24:789.
    >> Share

  541. MRABTI H, Sauvaget C, Bendahhou K, Selmouni F, et al
    Breast cancer treatment and its impact on survival in Morocco: a study over a decade.
    BMC Cancer. 2024;24:786.
    >> Share

    June 2024
  542. OZORIO DUTRA SV, Schwab L, Coury J, Ji M, et al
    Process evaluation protocol plan for a home-based physical activity intervention versus educational intervention for persistent taxane-induced peripheral neuropathy (B-HAPI study): a randomized controlled trial.
    BMC Cancer. 2024;24:777.
    >> Share

  543. BOHANSKE MS, Momenzadeh K, van der Zwaal P, Hoogwater FJH, et al
    Computed tomography-based structural rigidity analysis can assess tumor- and treatment-induced changes in rat bones with metastatic lesions.
    BMC Cancer. 2024;24:767.
    >> Share

  544. MASHAYEKH-AMIRI S, Jafarabadi MA, Hosseinzadeh M, Kanani ES, et al
    Measurement properties of the Iranian version of the breast cancer perception scale (BCPS) according to the COSMIN checklist.
    BMC Cancer. 2024;24:743.
    >> Share

  545. CANINO F, Barbolini M, De Giorgi U, Fontana T, et al
    Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study.
    BMC Cancer. 2024;24:735.
    >> Share

  546. JORIS S, Giron P, Olsen C, Seneca S, et al
    Identification of RAD17 as a candidate cancer predisposition gene in families with histories of pancreatic and breast cancers.
    BMC Cancer. 2024;24:723.
    >> Share

  547. XU C, Sun L, Wang H, Sun J, et al
    Identifying the mechanism of polysaccharopeptide against breast cancer based on network pharmacology and experimental verification.
    BMC Cancer. 2024;24:726.
    >> Share

  548. KANG Z, Jin Y, Yu H, Li S, et al
    Relative efficacy of antibody-drug conjugates and other anti-HER2 treatments on survival in HER2-positive advanced breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:708.
    >> Share

  549. LI Y, Han D, Shen C
    Prediction of the axillary lymph-node metastatic burden of breast cancer by (18)F-FDG PET/CT-based radiomics.
    BMC Cancer. 2024;24:704.
    >> Share

  550. XU JX, Zhu QL, Bi YM, Peng YC, et al
    New evidence: Metformin unsuitable as routine adjuvant for breast cancer: a drug-target mendelian randomization analysis.
    BMC Cancer. 2024;24:691.
    >> Share

  551. YE J, Ying J, Chen H, Wu Z, et al
    PPIH acts as a potential predictive biomarker for patients with common solid tumors.
    BMC Cancer. 2024;24:681.
    >> Share

    May 2024
  552. AZIZ MA, Chowdhury S, Jafrin S, Barek MA, et al
    Genetic association of Interleukin-17A polymorphism in Bangladeshi patients with breast and cervical cancer: a case-control study with functional analysis.
    BMC Cancer. 2024;24:660.
    >> Share

  553. YU S, Yue Z, Liu Q
    Pectinose induces cell cycle arrest in luminal A and triple-negative breast cancer cells by promoting autophagy through activation of the p38 MAPK signaling pathway.
    BMC Cancer. 2024;24:639.
    >> Share

  554. KUEMMEL S, Harper-Wynne C, Park YH, Franke F, et al
    heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-po
    BMC Cancer. 2024;24:641.
    >> Share

  555. LAMBERT V, Kane S, Howidi B, Nguyen BN, et al
    Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
    BMC Cancer. 2024;24:631.
    >> Share

  556. ZHENG M, Wu L, Xiao R, Cai J, et al
    Fbxo45 facilitates the malignant progression of breast cancer by targeting Bim for ubiquitination and degradation.
    BMC Cancer. 2024;24:619.
    >> Share

  557. WANG Q, Chen H, Yang Q, Qiu J, et al
    Awareness and associated factors of venous thromboembolism in breast cancer surgical patients: a cross-sectional study.
    BMC Cancer. 2024;24:610.
    >> Share

  558. EL HABRE R, Aoun R, Tahtouh R, Hilal G, et al
    All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells.
    BMC Cancer. 2024;24:615.
    >> Share

  559. BOUTRUS RR, Abdelazim YA, Mohammed T, Bayomy M, et al
    The impact of loco-regional treatment modality on the outcomes in breast cancer patients younger than forty years of age.
    BMC Cancer. 2024;24:599.
    >> Share

  560. HAUNER D, Mang A, Donik L, Schederecker F, et al
    Dietary supplement intake in women with breast cancer before and after diagnosis: results from the SUCCESS C trial.
    BMC Cancer. 2024;24:591.
    >> Share

  561. SAHU RK, Tandon S, Singh S, Das BC, et al
    Methyl CpG binding protein MBD2 has a regulatory role on the BRCA1 gene expression and its modulation by resveratrol in ER+, PR+ & triple-negative breast cancer cells.
    BMC Cancer. 2024;24:566.
    >> Share

  562. SBAITY E, Tamim H, El-Hajj Fuleihan G, Abbas J, et al
    Effect of young age (below 40 years) on oncologic outcomes in Lebanese patients with breast cancer: a matched cohort study.
    BMC Cancer. 2024;24:560.
    >> Share

  563. WANG J, Tian C, Zheng BJ, Zhang J, et al
    The use of longitudinal CT-based radiomics and clinicopathological features predicts the pathological complete response of metastasized axillary lymph nodes in breast cancer.
    BMC Cancer. 2024;24:549.
    >> Share

    April 2024
  564. HAN JY, Che N, Mo J, Zhang DF, et al
    Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer.
    BMC Cancer. 2024;24:532.
    >> Share

  565. ZOU J, Chen Q, He Y, Pan Y, et al
    Systematic optimization and evaluation of culture conditions for the construction of circulating tumor cell clusters using breast cancer cell lines.
    BMC Cancer. 2024;24:507.
    >> Share

  566. GILL J, Yendamuri K, Chatterjee U, Yao S, et al
    Racial/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.
    BMC Cancer. 2024;24:461.
    >> Share

  567. LIU Z, Li J, Zhao F, Ren D, et al
    Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis.
    BMC Cancer. 2024;24:440.
    >> Share

  568. LI B, Dai S, Wang Q, Jing H, et al
    Investigation of correlation between shear wave elastography and lymphangiogenesis in invasive breast cancer and diagnosis of axillary lymph node metastasis.
    BMC Cancer. 2024;24:409.
    >> Share

  569. WU Z, Zhang Q, Jin Y, Zhang X, et al
    Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area.
    BMC Cancer. 2024;24:411.
    >> Share

  570. QIU C, Wang W, Xu S, Li Y, et al
    Construction and validation of a hypoxia-related gene signature to predict the prognosis of breast cancer.
    BMC Cancer. 2024;24:402.
    >> Share

    March 2024
  571. ESMAT E, Haidary AM, Saadaat R, Rizvi SN, et al
    Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: a cross-sectional study in a tertiary care hospital, Kabul, Afghanistan.
    BMC Cancer. 2024;24:388.
    >> Share

  572. ZAHEDI H, Alizadeh-Dibazari Z, Mirghafourvand M, Sahebihagh MH, et al
    The effectiveness of couple-based interventions on the marital outcomes of women with genital and breast cancer and their partners: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:391.
    >> Share

  573. CHEHELGERDI M, Khorramian-Ghahfarokhi M, Dehkordi FB, Chehelgerdi M, et al
    Comment on "A novel super-enhancer-related gene signature predicts prognosis and immune microenvironment for breast cancer".
    BMC Cancer. 2024;24:377.
    >> Share

  574. HUANG W, Wang C, Shen Y, Chen Q, et al
    Correction: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
    BMC Cancer. 2024;24:378.
    >> Share

  575. REN H, Wang Z, Zhang L, Zhu G, et al
    Clinical significance of low expression of CADM3 in breast cancer and preliminary exploration of related mechanisms.
    BMC Cancer. 2024;24:367.
    >> Share

  576. WANG Y, Men X, Gu Y, Wang H, et al
    Retraction Note: Haplotype analysis on correlation between transcription factor 7-like 2 gene polymorphism and breast cancer risk.
    BMC Cancer. 2024;24:366.
    >> Share

  577. CHANDRAN G, Tang N, Ngo ELP, Huang S, et al
    Comparing the efficacy of a multi-dimensional breast cancer rehabilitation programme versus a home-based exercise programme during adjuvant cancer treatment.
    BMC Cancer. 2024;24:361.
    >> Share

  578. LOFT LH, Pedersen LH, Bigaard J, Bojesen SE, et al
    Attitudes towards risk-stratified breast cancer screening: a population-based survey among 5,001 Danish women.
    BMC Cancer. 2024;24:347.
    >> Share

  579. WANG ZQ, Wu ZX, Wang ZP, Bao JX, et al
    Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis.
    BMC Cancer. 2024;24:353.
    >> Share

  580. OPUTA CH, Peters E, Otovwe A
    Effect of educational intervention on the knowledge, attitude and practice of breast self-examination among female students at a private university in Southern Nigeria.
    BMC Cancer. 2024;24:355.
    >> Share

  581. BOULIFA A, Raftery MJ, Franzen AS, Radecke C, et al
    Role of beta-(1-->3)(1-->6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D cultures.
    BMC Cancer. 2024;24:339.
    3)(1-->6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D cultures.&body=BOULIFA A, Raftery MJ, Franzen AS, Radecke C, et al. Role of beta-(1-->3)(1-->6)-D-glucan derived from yeast on natural killer (NK) cells and breast cancer cell lines in 2D and 3D cultures. BMC Cancer. 2024;24:339. https://pubmed.ncbi.nlm.nih.gov/38486205" ALT="Email" TITLE="Email"> --> >> Share

  582. KNUDSEN BM, Sondergaard SR, Stacey D, Steffensen KD, et al
    Impact of timing and format of patient decision aids for breast cancer patients on their involvement in and preparedness for decision making - the IMPACTT randomised controlled trial protocol.
    BMC Cancer. 2024;24:336.
    >> Share

  583. MAENPAA N, Tiainen L, Hamalainen M, Luukkaala T, et al
    Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer.
    BMC Cancer. 2024;24:331.
    >> Share

  584. PALMER S, Blomqvist C, Holmqvist M, Lindman H, et al
    Validation of primary and outcome data quality in a Swedish population-based breast cancer quality registry.
    BMC Cancer. 2024;24:329.
    >> Share

  585. KANG D, Wang C, Han Z, Zheng L, et al
    Exploration of the relationship between tumor-infiltrating lymphocyte score and histological grade in breast cancer.
    BMC Cancer. 2024;24:318.
    >> Share

  586. GOH SP, Ong SC, Chan JE
    Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review.
    BMC Cancer. 2024;24:316.
    >> Share

  587. SHITRIT IB, Wang A, Ilan K, Agassi R, et al
    Epidemiological, clinical, and pathological characteristics of invasive breast cancer in Bedouin and Jewish women in southern Israel: a retrospective comparative study.
    BMC Cancer. 2024;24:310.
    >> Share

  588. KHANNA D, Sharma P, Budukh A, Vishwakarma R, et al
    Rural-urban disparity in cancer burden and care: findings from an Indian cancer registry.
    BMC Cancer. 2024;24:308.
    >> Share

  589. MOLIERE S, Lodi M, Leblanc S, Gressel A, et al
    MMP-11 expression in early luminal breast cancer: associations with clinical, MRI, pathological characteristics, and disease-free survival.
    BMC Cancer. 2024;24:295.
    >> Share

  590. MESHKANI Z, Moradi N, Aboutorabi A, Farabi H, et al
    A cost-benefit analysis of genetic screening test for breast cancer in Iran.
    BMC Cancer. 2024;24:279.
    >> Share

  591. REN J, Chen W, Zhou Y, Sun J, et al
    The novel circRNA circ_0045881 inhibits cell proliferation and invasion by targeting mir-214-3p in triple-negative breast cancer.
    BMC Cancer. 2024;24:278.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016